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Abstract 
Folliculogenesis is the ovarian process in which a follicle, consisting of an oocyte 
surrounded by granulosa cells (GCs), theca cells, a fluid-filled antrum, and a basal lamina 
separating GCs from TCs, grows and differentiates, culminating in development of a 
fertilizable oocyte. TCs under the influence of luteinizing hormone (LH) produce 
androgens. GCs under the influence of follicle stimulating (FSH) hormone proliferate, 
produce steroid hormones, and differentiate to become responsive to the surge of LH that 
initiates ovulation. The cellular processes of folliculogenesis require cell-extracellular 
matrix (ECM) interactions. Spondin 1 (SPON1) is an ECM protein primarily studied for 
its role in nervous system development as a nerve outgrowth signalling molecule, but is 
also known to affect cell viability, differentiation, and migration in non-neural tissues and 
cells. Evidence that Spondin 1 is functional within the ovary includes its discovery in 
bovine follicular fluid, its increased mRNA expression in response to estrogen in uterus 
and mammary gland, its decreased mRNA expression in GCs of mice null for estrogen 
receptor β, and its overexpression in ovarian cancer. Despite the possible importance of 
Spondin 1 in the ovary it has never been characterized in this tissue. This study was 
undertaken with the goal of elucidating roles of Spondin 1 in the ovary. Experiments with 
the human GC tumour cell line, KGN, found that Spondin 1 increases cell viability and 
proliferation possibly by activating the mTORC1 complex, and decreases cAMP-induced 
progesterone production by inhibiting cAMP-induced STAR transcription. Experiments 
with mouse primary GCs corroborated the effects of Spondin 1 on granulosa cell viability 
and again found a role for Spondin 1 in steroidogenesis, however, progesterone 
production was increased in these cells. Interestingly, Spondin 1 co-localized with 
vasculature markers in the mouse ovary and uterus, two of only a few tissues where the 
vascular network is dynamic, suggesting a role in angiogenesis. Finally, characterization 
of the reproductive phenotype of Spon1
-/- 
females revealed that loss of Spondin 1 results 
in subfertility marked by smaller litter sizes, decreased ovulation capacity, and smaller 
ovarian weight.  These findings support an important role for Spondin 1 in ovarian 
folliculogenesis and maintenance of optimal fertility. 
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1 Chapter 1: Introduction 
 
1.1 Folliculogenesis Overview 
Ovarian folliculogenesis is the coordinated growth and development of somatic 
and germ cells from primordial germ cells surrounded by a single layer of squamous pre-
granulosa cells to a preovulatory follicle comprised of theca cells (TCs), cuboidal 
differentiated granulosa cells (GCs) and an oocyte capable of fertilization. An oocyte 
proceeds through several follicular stages before ovulation occurs: primordial germ cell, 
primordial follicle, primary follicle, secondary follicle, and antral/preovulatory follicle 
(Figures 1-1 and 1-2). After ovulation follicular remnants that were not expelled become 
the corpus luteum which produces progesterone to support pregnancy. A primordial 
follicle consists of an oocyte surrounded by a single layer of squamous pre-granulosa 
cells. In a primary follicle there is still only a single layer of cells surrounding the oocyte 
but they have differentiated to become cuboidal GCs. Once these GCs multiply to form a 
few layers and are surrounded by TCs (separated from GCs by a basal lamina) the follicle 
is known as a secondary follicle. An antral or preovulatory follicle consists of several 
layers of GCs and a fluid filled antrum with cumulus GCs surrounding the oocyte. The 
corpus luteum is highly vascularized and consists of luteinized granulosa and theca cells. 
Specific details of each stage are discussed in the following paragraphs. 
The process of folliculogenesis is dependent on the cooperative hypothalamic-
pituitary-gonadal axis in which the hypothalamus, pituitary and ovaries act as endocrine 
glands. At puberty, the hypothalamus begins releasing gonadotropin releasing hormone 
(GnRH) in pulses, signalling the pituitary to release the gonadotropins, follicle 
stimulating hormone (FSH) and luteinizing hormone (LH). Exposure of the ovary to FSH 
and LH results in the growth of follicles and follicular production of estrogen (primarily 
17β-estradiol) which feeds back to the pituitary affecting release of gonadotropins. 
Before ovulation occurs a pulse of LH is released by the pituitary and pre-ovulatory 
follicles expressing adequate levels of the LH receptor (LHR) undergo ovulation.  
 2 
 
 
 
 
Figure 1-1. The Follicle and Follicular Stages 
A) A representative antral follicle demonstrating parts of the follicle including: the oocyte, 
granulosa cells, theca cells, and the antrum. B) Stages of folliculogenesis.   
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Figure 1-2. Overview of Folliculogenesis 
An overview of folliculogenesis from primordial follicle to corpus albicans. The oval 
represents the ovary and the tube-like structure above and to the right represent the uterus 
and a fallopian tube. 1) primordial follicles 2) primary and secondary follicles 3) antral or 
preovulatory follicle 4) ovulation 5) corpus luteum 6) corpus albicans. 
https://commons.wikimedia.org/wiki/File:Order_of_changes_in_ovary.svg 
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GCs and TCs that are not lost when ovulation occurs differentiate under the influence of 
LH to granulosa lutein and theca lutein cells. Lutein cells produce high levels of 
progesterone required by the uterus during early pregnancy. Only a small number of 
oocytes complete folliculogenesis and are ovulated. The majority are lost to atresia at 
various stages throughout the process. 
1.1.1 Epiblast to Primordial Follicle 
During early mammalian embryonic development primordial germ cells (PGCs) 
arise from the epiblast. Differentiation of epiblasts into PGCs in mice is determined by 
signalling of bone morphogenetic proteins (BMP), BMP2, BMP4, and BMP8B [1].  
These PGCs migrate toward the undifferentiated gonad from the yolk sac. Once at the 
gonad they proliferate from only a few dozen cells to several thousand in mice [2] and 
several million in humans [3]. If their fate is to become oogonia they undergo several 
rounds of mitosis and then differentiate into oocytes and enter and arrest in prophase I of 
meiosis [4, 5], while spermatogonia proliferate and then become quiescent. PGC 
proliferation is regulated by several different signalling proteins including activin, 
inhibin, BMPs, and transforming growth factor β, (TGFβ) [6-9]. However, there is 
evidence that the specific pathways that affect proliferation are not conserved between 
different animals, as activin increases proliferation in humans [8] but decreases it in mice 
[6].  
Differentiation of PGCs to either oogonia or spermatogonia is determined by 
several sex determining factors. The process of sex determination has recently been 
revealed to be much more complex than the previously accepted notion of a default 
female pathway. In the previous model of sex determination presence of the sex 
determining region Y (SRY) gene in the genome resulted in suppression of development 
of female structures by anti-mullerian hormone (AMH) [10, 11] and initiation of testis 
development, while absence of SRY resulted in the default development of ovaries and 
other female anatomy. SRY is indeed required to activate the signalling cascade that 
begins testis development but now it is known that the developing and developed ovary 
expresses male-suppressing genes. Notably, in the absence of either wingless type 
MMTV integration site family, member 4 (WNT4) or R-spondin (RSPO1) in mice the 
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ovary undergoes sex-reversal to a more testicular phenotype [12-15]. While loss of 
forkhead box L2 (FOXL2) in adulthood results in partial sex reversal with ovarian cells 
differentiating to testis cell types [16]. Interestingly, male-to-female sex reversal in seen 
in genotypically XY mice stably overexpressing β-catenin (a downstream target of WNT) 
[17]. It is likely these above mentioned proteins signal to the PGCs to differentiate to 
oogonia or spermatogonia. 
Proliferation of PGCs in the mammalian primordial ovarian gonad results in the 
formation of syncytia or “nests of cells” that arise due to incomplete cytokinesis 
producing intercellular bridges ([18], reviewed in [19]). After nests are formed cells enter 
meiosis. In mice this occurs around 13.5 days post coitus (dpc) [20] and in humans it is 
around 13 weeks of gestation [21]. These nests break down to generate primordial 
follicles perinatally in mice [22] and in the second trimester in humans [23]. At this stage 
the majority of PGCs are lost to atresia with only 33% of mouse cells [22] and only two 
million cells in humans surviving to become primordial follicles [3]. This loss of cells is 
not random and mechanisms are in place to ensure that the “healthiest” cells go on to 
become primordial follicles. In Drosophila nests, all cells save one become nurse cells 
and provide cellular components such as nutrients and mitochondria to the future oocyte 
before undergoing apoptosis [24]. A similar mechanism has been seen in mice where 
programmed synchronous nest breakdown is accompanied by movement of mitochondria 
through intercellular bridges [22, 25]. While the nests are breaking down, surrounding 
somatic cells invade the nests and eventually surround the oocyte. This forms the 
primordial follicle consisting of a single oocyte with a single layer of epithelial pre-
granulosa cells [4, 22].  
 
1.1.2 Primordial Follicle to Secondary Follicle 
To maintain fertility primordial follicles remain quiescent for months or even 
decades, depending on the species, before being activated to become primary follicles.  
The exact mechanisms that allow for activation of one primordial follicle but not its 
neighbour are still being discovered. Several proteins and pathways are known to be 
involved in suppressing activation of primordial follicles. AMH, while not expressed in 
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the ovary during development, is expressed postnatally [26] and suppresses formation of 
primary follicles [27]. Loss of AMH results in over-activation of primordial follicles [28] 
while overexpression of AMH inhibits activation and decreases FSH responsiveness of 
early follicles [29]. Over-activation of the primordial follicle pool is also seen in mice 
lacking forkhead box O3,  Foxo3a [30] and mice lacking phosphatase and tensin 
homolog, Pten in oocytes [31]. The mammalian target of rapamycin (mTOR) complex 1 
(mTORC1) pathway is involved in maintaining dormancy as loss of tuberous sclerosis 1, 
Tsc1 [32] or -2, Tsc2 [33], repressors of mTOR, results in activation of the entire pool. 
Further studies into these pathways should yield insight into the dynamics of primordial 
follicle activation. 
When a primordial follicle is activated the somatic, squamous pre-granulosa cells 
differentiate into a single layer of cuboidal GCs forming a primary follicle. In mice with 
inactivation of FOXL2 oocytes prematurely grow while pre-granulosa cells do not 
differentiate to GCs [34], suggesting that FOXL2 is one of the factors responsible for 
initiating granulosa cell differentiation. Secondary follicles are formed when the GCs 
proliferate to more than one layer of cells and when TCs surround GCs. Granulosa cell 
proliferation requires oocyte-produced growth and differentiation factor 9, (GDF9) as 
follicles in mice null for Gdf9 never grow to the secondary stage [35]. The process of 
theca cell recruitment is not very well understood but signals from the GCs are believed 
to recruit stromal cells to differentiate into TCs [36]. Endothelial cells are also recruited 
to form a vascular network inside the TCs and outside of the basal lamina of the follicle. 
This vasculature delivers hormones and nutrients and is essential for the survival and 
further growth of follicles [37, 38].  
 
1.1.3 Secondary Follicle to Pre-ovulatory Follicle 
Growth of a follicle to the pre-ovulatory stage is dependent on the ability of GCs 
to respond to FSH and TCs to respond to LH, and therefore depends on the expression of 
follicle stimulating hormone receptor (FSHR) and LHR. Mice lacking either the ability to 
produce FSH (Fshb
-/-
) or the ability to respond to FSH (Fshr
-/-
) fail to produce follicles 
past the secondary stage [39, 40]. Follicles in mice unable to respond to LH only progress 
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to the early antral stage [41]. Through the combined actions of FSH and LH, follicles 
grow, produce steroids, and form a fluid-filled antrum.  
The primary function of TCs after the secondary follicle stage is to collect 
cholesterol from the blood supply and produce androgens, specifically androstenedione 
and testosterone as precursors for 17β-estradiol production in GCs. GCs also produce 
progesterone, which may be used by TCs as a substrate for androgen production. The 
expression of steroidogenesis enzymes in TCs is reliant on the response of TCs to LH. 
Several factors are known to increase LHR levels in TCs, including insulin-like growth 
factor 1 (IGF1), stem cell factor (SCF), and inhibin. These proteins are produced by GCs 
suggesting that GCs continue to regulate TC differentiation after recruitment [42]. 
Granulosa cells respond to the increase in androgens by expressing FSHR [43]. Then in 
response to FSH, GCs proliferate and express steroidogenesis genes to produce 17β-
estradiol. Cooperative steroid hormone production by TCs and GCs in response to LH 
and FSH, respectively, is known as the two-cell, two-gonadotropin theory (Figure 1-3).  
 The formation of the antrum is not well understood but both GCs and TCs are 
thought to be involved. One theory is that GCs create an osmotic gradient by producing 
molecules such as hyaluronan and versican which drives movement of fluid from the 
vascular network within the TCs into the follicle [44]. Follicular fluid is similar to serum 
in its composition although plasma proteins larger than 100 kDa are found at lower 
concentrations suggesting a barrier to movement of larger molecules [45]. The GCs that 
surround the oocyte after formation of the antrum are known as cumulus cells or the 
cumulus oophorus while the cells closer to the basal lamina are termed mural cells. In 
response to FSH, mural GCs produce high levels of 17β-estradiol and express LHR. 
Cumulus GCs do not produce as many steroids as mural GCs but provide nutrients and 
protection to the oocyte [46]. 
Feedback from the follicle to the pituitary is required for the follicle to reach the 
pre-ovuylatory stage.  As granulosa cells proliferate, 17β-estradiol levels increase and 
affect production of GnRH at the hypothalamus. High levels of 17β-estradiol result in 
lower production of FSH and higher production of LH. Granulosa cells also affect 
gonadotropin production through signalling of TGFβ family members, activin and 
inhibin, so named for their effects on FSH. Small follicles and early antral follicles  
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Figure 1-3. The two-cell, two-gonadotropin model. 
Schematic diagram showing a theca cell (TC) and a granulosa cell (GC) responding to 
luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to make steroid 
hormones. TCs respond to LH by increasing cAMP signalling to make testosterone from 
cholesterol. Testosterone travels through the basal lamina to GCs where it is made into 
17β-estradiol (estradiol) under the influence of FSH. Estradiol is then released into 
circulation. GCs also make progesterone from cholesterol to be released into circulation 
and as a substrate for TC androgen production. 
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express more activin while late-antral/pre-ovulatory follicles express more inhibin and 
therefore suppress production of FSH. The end result of gonadotropin-dependent 
follicular growth is a pre-ovulatory follicle that produces high levels of 17β-estradiol and 
inhibin to stimulate a large surge of LH from the pituitary and expresses enough LHR to 
respond to that surge.  
 
1.1.4 Ovulation – Corpus Luteum – Corpus Albicans 
In follicles capable of response, the LH surges results in oocyte maturation, 
expansion of the cumulus GCs, ovulation, and luteinization of GCs and TCs. LH rapidly 
changes expression of a myriad of genes [47] and activates several pathways that work 
both cooperatively and parallel to each other to begin these processes. The initial signal 
that activates these pathways is signalling of the LHR in mural granulosa cells [48] to 
guanine nucleotide-binding proteins (G proteins) which increase the levels of cAMP [49]. 
The pathways activated by this signalling include the protein kinase A (PKA), 
phosphoinositide-3 kinase/protein kinase B (PI3K/AKT), and RAS pathways [4]. Several 
molecules within these pathways are known to be required for a full response to LH. For 
example, secretion, in mural GCs, of the epidermal growth factor (EGF)-like growth 
factors, epiregulin (EREG), amphiregulin (AREG) and betacellulin (BCT) is induced by 
LH signalling [50]. These factors activate EGF receptors in cumulus cells [51], and 
disruption of the EGF-pathway blocks ovulation [52]. LH-dependent activation of 
extracellular signal-regulated kinase (ERK)1/2 via multiple signalling pathways is 
essential for oocyte maturation, cumulus expansion, and ovulation [53]. 
  
Oocyte Maturation. During primordial germ cell formation, the oocytes arrest at 
Prophase I of meiosis. Following the LH surge oocytes resume meiosis and then arrest 
again at Metaphase II until fertilization or death. Maintenance of arrest and resumption of 
meiosis following the LH surge is not fully understood but factors derived from the 
follicle have been discovered. The first evidence that follicle-derived factors were 
involved in maintenance of arrest was that oocytes removed from large follicles of rabbits 
and cultured in nutrients spontaneously resumed meiosis [54], suggesting that loss of 
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some follicle factor(s) results in oocyte maturation. This finding has since been 
confirmed in numerous species. The cyclic nucleotides, cAMP and cGMP, regulate 
oocyte maturation. High levels of cAMP are required to maintain arrest and must be 
produced by the oocyte itself [55] as cumulus GC cAMP production alone is not 
sufficient to maintain arrest [56]. Resumption of meiosis is coincident with reduction in 
cAMP levels and maintaining high levels of cAMP stops spontaneous meiosis in cultured 
oocytes [57, 58]. Meiotic resumption is also accompanied by a decrease in cGMP, and 
injection with cGMP maintains arrest in rat oocytes [59]. cGMP agonists have no effect 
in oocyte culture but impair arrest in cumulus oocyte complex (COC) culture suggesting 
that cGMP is derived from somatic cells [60]. cGMP inhibits breakdown of cAMP in 
oocytes [61]. High levels of cGMP in cumulus GCs are produced through the action of 
natriuretic peptide receptor B/guanylate cyclase B, NPR2 which is stimulated by 
natriuretic peptide precursor C, NPPC, produced in mural GCs [62]. The LH surge 
decreases activity of NPPC and NPR2, decreasing cGMP levels, which in turn decreases 
cAMP levels and re-activates meiosis [63, 64]. 
 
Cumulus Expansion and Dissociation. Following the LH surge, cumulus GCs 
produce proteins to enrich their extracellular matrix (ECM) in preparation for ovulation. 
The process is termed cumulus expansion due to the increased volume of the COC. The 
enriched ECM contains high amounts of hyaluronan (HA) as well as ECM proteins such 
as laminin, collagen IV, fibronectin, and proteoglycans. The production of these proteins 
is dependent on altered signalling in both cumulus GCs and the oocyte [65, 66] and 
several knockout mouse models have elucidated genes essential to this process. 
Prostaglandin signalling, activated by ERK1/2 [67], induces cumulus GCs to produce 
ECM proteins [68]. Prostaglandin endoperoxide synthase 2, Ptgs2, null mice are infertile 
due to failure of cumulus expansion and ovulation [69] and prostaglandin E2 receptor, 
Ptger2, null mice are subfertile due to incomplete cumulus expansion [70]. Loss of the 
tumour necrosis factor, alpha induced protein 6, Tnfaip6, which interacts with 
hyaluronan, in mice results in infertility as well [71]. Isolated COCs with poor cumulus 
expansion or oocytes with loss of cumulus GCs are unfertilizable [72]; the former due to 
an inability of sperm to degrade the hyaluronan-rich ECM while the latter suggests that 
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cumulus GCs maintain viability of the oocyte. Concurrent with expansion, the COC 
dissociates from the surrounding follicle resulting in an oocyte surrounded by a single 
layer of expanded cumulus GCs [73]. 
 
Ovulation. Ovulation involves expulsion of the COC from the follicle and from 
the ovary itself. Several changes within the follicle must occur before ovulation including 
cumulus expansion and dissociation, breakdown of the ECM surrounding mural GCs and 
TCs, and possibly, increases in intrafollicular pressure. Following the LH surge the ECM 
is degraded by proteinase activity [74-76], primarily matrix metalloproteinases (MMPs) 
[77] and tissue inhibitors of metalloproteinases (TIMPs) [77, 78]. The ECM surrounding 
apical (closer to the ovarian epithelium) GCs, TCs, and cells of the surface epithelium of 
the ovary is degraded to allow for rupture and expulsion of the COC [77, 79]. The 
specific mechanism for localized degradation is still unclear but may result from 
localized expression of TIMPs [78]. The a disintegrin and metalloproteinase with 
thrombospondin motifs (ADAMTS) family has recently begun to be studied for its role in 
ECM degradation during ovulation. Currently only ADAMTS-1 has been found to be 
essential for ovulation [80-82] but other family members are hypothesized to be involved. 
A much-debated hypothesis is that follicular fluid increases following LH surge and 
increases intrafollicular pressure providing the force for ovulation to occur [83, 84].  
 
Luteinization and Angiogenesis. After ovulation, GCs and TCs undergo 
differentiation to granulosa lutein (GL) and theca lutein (TL) cells in a process called 
luteinization. Endothelial cells enter the follicle and form capillaries by angiogenesis, the 
growth of new blood vessels from existing ones. The new structure created by 
luteinization and angiogenesis is called the corpus luteum (CL). Corpus luteum, meaning 
yellow body, is named due to the high amount of cholesterol required to produce high 
levels of progesterone to prepare the endometrium for implantation and pregnancy. If 
fertilization does not occur the CL regresses and becomes a corpus albicans (white body), 
and if fertilization occurs the CL continues to make progesterone until the placenta can 
produce its own. Following successful fertilization and implantation, the length of time 
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that the CL remains functional is dependent on the species but in all cases loss of the CL 
in early pregnancy results in loss of pregnancy.  
The process of luteinization varies between species but the overall mechanisms 
are thought to be similar [85]. Again in luteinization, the LH surge signal is thought to be 
propagated by an increase in cAMP. The first marker of differentiated GLs and TLs is 
exit from the cell cycle as the main purpose of luteal cells is to produce progesterone. In 
most species, a marker of luteinization is loss of steroidogenesis enzymes responsible for 
steroid production downstream of progesterone: androgens in TLs and estrogens in GLs. 
However, in many primates production of androgens and estrogens is maintained 
following luteinization [86-89]. Genes involved in uptake and metabolism of cholesterol 
are upregulated in both TLs and GLs. For example, in GLs, production of steroid acute 
regulatory protein, StAR, not highly expressed in non-luteinized GCs, is essential for 
luteinization as GLs acquire the capability to produce large amounts of progesterone. 
Within species there is variation in the extent to which GLs and TLs can be distinguished. 
In several species, the GLs are larger hypertrophied cells that produce more progesterone 
and the TLs remain smaller, while in rodents the large and small luteal cell populations 
differ in progesterone output but cannot be traced to initial GC and TC populations [86, 
90-93].  
To acquire large amounts of cholesterol as a substrate for progesterone and to 
better act as a paracrine gland the corpus luteum must become vascularized. Prior to 
ovulation, the vasculature of the follicle exists only in the TCs and does not penetrate the 
basal lamina. After ovulation, endothelial cells create new capillaries that invade the 
follicle along with the TCs. The primary factor that initiates angiogenesis is vascular 
endothelial growth factor, VEGF. VEGF expression is turned on during differentiation of 
GCs to GLs, while endothelial cells express the VEGF receptors, VEGFR1 and VEGFR2 
suggesting that these cells signal to the endothelial cells to invade the CL [94-97]. While 
VEGF initiates angiogenesis, several other factors are important in regulating capillary 
growth including angiopoietins (ANGPT), vascular endothelial-cadherin (VE-cadherin) 
and thrombospondins. Angiopoietins, ANGPT-1 and ANGPT-2 stabilise new vessels and 
destabilise existing vessels, respectively [98, 99]. VE-cadherin is a cell adhesion 
molecule that is required for proper vessel development and whose inhibition by antibody 
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in mice results in loss of follicular vascularization [100]. Thrombospondins, TSP-1 and 
TSP-2, are anti-angiogenic factors within the ovary and expressed in GCs of small 
follicles. Expression patterns of TSP-1 and -2 differ by species, with bovine CLs having 
no expression [101] while rats express it in early but not late CLs [102]. Although 
currently unknown, it is likely that downregulation of TSP-1 and -2 is required for 
normal CL vascularization.   
 
1.1.5 ECM Proteins and Folliculogenesis 
The complex process of folliculogenesis involves proper functioning of the 
extracellular matrix (ECM) both between cells and at the basal lamina. As mentioned in 
1.1.5, changes to the ECM are essential for cumulus expansion and ovulation. But the 
frequent tissue remodelling, cell growth, and differentiation required for preparing an 
oocyte for fertilization necessitates compositional changes and altered signalling of the 
ECM throughout folliculogenesis. ECM proteins affect cellular proliferation, survival, 
morphology, and steroidogenesis. ECM proteins are highly variable, with some proteins 
serving as structural components and others primarily as signalling molecules.  
The ECM of each tissue is unique but within the follicle there is a highly 
specialized type of matrix called the focimatrix [103]. The ECM usually completely 
surrounds cells or cellular structures in most tissues but the focimatrix exists as small 
deposits of unique matrix between GCs. These deposits increase in size and number as 
the follicle grows [103] and are found in different amounts depending on cellular location 
[104]. As well, expression of focimatrix genes has been correlated with expression of 
steroidogenesis genes [104, 105]. These data suggest that the focimatrix plays a 
significant role in granulosa cell function although that role is not yet clear. 
Proper functioning of the basal lamina is essential for maintaining the blood-
follicle barrier until ovulation occurs. Although the blood-follicle barrier was first noted 
almost 50 years ago, its exact mechanisms remain largely unknown [106]. It is generally 
understood that size is a determinant of permeability; however different molecular 
weights from 100-500 kDa have been reported as the minimum size. The charge of a 
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molecule is also important with negatively charged proteins being excluded from 
transiting the barrier. 
Structural proteins within the ovarian ECM include, but are not limited to, 
collagens, fibronectin, laminins, nidogens, and perlecan. Along with proteoglycans 
(which are mostly heparin sulfate proteoglycans in the follicle), these proteins form the 
scaffolding of the matrix. A second role of these proteins is cellular signal transduction 
achieved through direct or indirect interaction with cell surface proteins, primarily 
integrins. Several studies of artificial matrices containing various ECM proteins have 
shown the effects of these proteins on proliferation, adhesion, and morphology of GCs or 
ovarian tissue as well as steroid production of GCs [107-112]. As previously mentioned, 
matrix metalloproteinases (MMPs), and their inhibitors, TIMPs are required for ECM 
breakdown and therefore turnover and remodelling of ECM components [113]. 
Over the past two decades, the ECM has been recognized for its importance not 
only in structural integrity but in signal transduction as well. A second group of proteins 
not involved in structure within the ECM has begun to be extensively studied. Examples 
of important ECM signalling molecules within the ovary include thrombospondins, TSP-
1 and TSP-2, R-spondin, secreted protein acidic and rich in cysteine (SPARC), and 
ADAMTS proteins.  
Several null mouse models of ECM proteins show that specific proteins are 
essential for normal folliculogenesis. However, even more numerous are examples of 
ECM proteins whose functions are so important that loss is lethal or results in mild or no 
phenotypic changes to fertility due to redundancy.  
 
1.2 Spondin 1 
1.2.1 The Protein 
1.2.1.1 Identification 
Spondin 1 (protein symbol SPON1), encoded by Spon1, was first identified in 
1992 as a secreted ECM protein highly expressed in the rat floorplate where several 
aspects of the developing nervous system are controlled [114]. Therefore it is 
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unsurprising that currently the majority of published research about Spondin 1 concerns 
its role in the early nervous system. Spondin 1 was initially named F-spondin [114] after 
its location in the floorplate of the neural tube (F) and its thrombospondin repeats 
(spondin) (see Structure below) and is also known as vascular smooth muscle cell growth 
promoting factor or VSGP [115]. Spondin 1 is a thrombospondin type 1 repeat 
superfamily member and is considered part of the neuronal subclass of that family. 
Spondin 1 is highly conserved, with a homologous protein found in over 140 species of 
mammals, birds, fish, amphibians and insects.  
1.2.1.2 Structure 
Spondin 1 is comprised of 807 amino acids, with a hydrophobic N-terminal leader 
sequence, a consensus signal peptide cleavage site and no other hydrophobic regions 
[114]. For these reasons it was initially determined and then proven to be a secreted 
protein. The 807 amino acids can be divided into three regions. The first 1-200 amino 
acids are similar to a region in Reelin which has been referred to in Spondin 1 as the 
“reelin domain” and in Reelin as the “F-spondin domain” and will be referred to here as 
the “reeler domain” [116]. Amino acids 201-400 share similarity with a domain in 
Spondin 2, also known as Mindin. This domain is sometimes divided into two smaller 
domains and referred to as the FS1 and FS2 domains or is treated as a single domain 
called the FS or spondin domain [117-119]. Amino acids 441-807 comprise six 
thrombospondin type 1 repeat (TSR) domains. Studies of the crystal structure of the 
reeler domain found several arginine and lysine residues that provide surface positive 
charges for heparin binding and potentially other glycosaminoglycan (GAG) binding 
[120].  Evidence of weak dimerization of two reeler domains was also observed and it has 
been hypothesized that through binding of GAGs, Spondin 1 interaction with other GAG-
binding proteins could be facilitated [120]. The spondin domain, FS, is not well-studied 
but may play a role in nerve outgrowth signalling [121]. TSR domains are found in 
several proteins, including thrombospondins 1 and 2 (TSP-1, encoded by Thbs1; TSP-2, 
encoded by Thbs2), R-spondins, and ADAMTSs and are responsible for cellular 
adhesion, anti-angiogenic activity, tumour progression, and activation of TGFβ [122]. 
There are several regions within these TSRs that provide insight into its possible 
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functions. A CSVCTG motif is present in the fourth TSR while CSVSCG and CSACTG 
are found in the second and third. This motif inhibits angiogenesis and binds CD36 in 
TSP-1 [123, 124]. TSRs one, three, five, and six all contain basic residues and the crystal 
structures of five and six show that these residues all are located on one face of the 
domain. Therefore, these TSRs are predicted to bind heparin and other GAGs like the 
reeler domain [114, 122]. Each TSR contains a WxxW sequence, known to bind TGFβ. 
These tryptophan residues have also been indicated as potential sites for C-
mannosylation, while several serine and threonine residues are potentially O-fucosylated 
[125]. In TSRs one, four, and five these sequences are WSxWS which is also found in 
CNTF, LIF, and ILs, and mutation in IL2 results in loss of transmembrane signalling 
[114]. WSxW and a KRFK motif are found in the sixth TSR [122], and are required for 
latent TGFβ activation by Tsp-1 [126]. 
1.2.1.3 Proteins with Similar Domains 
 Spondin 1 shares domains with several proteins, most of which are members of 
the thrombospondin type 1 repeat domain (TSR) superfamily (Fig. 1-4). These proteins 
are ECM or transmembrane proteins and contain between one to twenty-five TSR 
domains [127]. A major role for many TSR proteins is in the nervous system [127]. A 
few TSR family members are discussed below, as well as the non-thrombospondin 
protein, Reelin.  
Thrombospondin 1 and 2 – TSP-1 and TSP-2 are thrombospondin family 
members defined as matricellular proteins because they exist within the ECM but do not 
contribute to its structural integrity. Instead, they are involved in cell-matrix signalling. 
TSP-1 and -2 are primarily recognized for their role as anti-angiogenic molecules but are 
also involved in cell adhesion and wound healing [128]. Tsp-1 also contains the WxxW 
and KRFK motifs responsible for binding and activating TGFβ [126]. As mentioned in 
1.1.4, both TSP-1 and TSP-2 are expressed in the ovary in a species-dependent manner. 
In rat, TSP-1 is expressed in GCs of early and late antral follicles and early but not late 
corpora lutea, while TSP-2 is seen in early corpora lutea [102]. Mice null for Thbs1 
produce fewer and smaller litters; however, these matings were homozygous and 
therefore it cannot be concluded if one or both sexes are subfertile [129]. 
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Figure 1-4. Spondin 1 and similar proteins; domain diagrams. 
Representative model of Spondin 1, showing its reeler, spondin, and TSR domains. 
Representative models of thrombospondin 1 (Tsp-1), R-spondin, Spondin 2, and Reelin, 
showing their reeler, spondin, or TSR domains, with other domains shown in grey.  
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R-spondin – The four R-spondins, R-spondin 1-4, are also neuronal TSR family 
members. Their name originates from the location of R-spondin 1 in the roofplate of the 
developing neural tube. The R-spondins have been primarily studied for their roles in 
Wnt signalling during embryogenesis [130]. Of the four R-spondins, R-spondin 1 is the 
most extensively studied for its role in gonadal development, and its loss can result in 
partial female-to-male sex reversal [12, 13]. R-spondin 3 and 4 have no known function 
in the ovary, but R-spondin 2 is expressed in the oocytes of primary to antral follicles and 
promotes follicle growth [131]. 
Spondin 2 - The spondin domain is only found in Spondin 1 and Spondin 2. 
Spondin 2 is the only protein with two domains of homology with Spondin 1 as it 
contains one TSR domain. Spondin 2 has not been extensively studied in any species but 
is known to bind integrins and block AKT signalling. It is also involved in disease 
processes in the immune system, heart, and kidney [132]. 
Reelin - Only Reelin, Spondin 1, and the minimally studied ferric-chelate 
reductase 1, (FRRS1) are known to share the reeler domain. The term reeler comes from 
a mutant mouse that had a “reeling” gait that was due to lack of functional Reelin [116]. 
Like Spondin 1, Reelin is involved in neural development and disorders. Recently, Reelin 
was found to be expressed in the bovine and chicken ovaries, primarily in the theca cells 
of larger follicles, and to promote chicken granulosa cell proliferation in culture [133, 
134].  
1.2.2 Neural Development and Growth 
As mentioned above, the majority of research published for Spondin 1 concerns 
its role in the nervous system. In 1992, the first paper to identify Spondin 1 did so in the 
floorplate of the embryonic day 13 (E13) rat embryo [114]. Along with mRNA 
expression in the floorplate, Spondin 1 was also found to be expressed in the spinal cord 
and peripheral motor and sensory nerves during their development [114]. Cells were 
transfected with myc-tagged Spondin 1 and this fusion protein was localized to the cell 
surface and in the medium suggesting that Spondin 1 is a membrane or ECM-associated 
secreted protein [114]. In one of the first demonstrations of its function, dorsal root 
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ganglia cells plated on purified Spondin 1 grew to a greater length than those plated on 
control proteins. Dorsal spinal cord cells adhered to Spondin 1 more than control bovine 
serum albumin (BSA) and this adhesion was diminished in the presence of heparin 
suggesting that Spondin 1 binds heparin [114]. These results were the first evidence that 
Spondin 1 regulates neural cell adhesion and nerve outgrowth. Subsequent work 
corroborated these findings in several different nerve types. Adhesion and outgrowth of 
neurons in the embryonic hippocampus is promoted by Spondin 1 [117]. Although 
expression diminishes after embryonic development, upregulation of Spondin 1 occurs 
during axon outgrowth of peripheral nerves following injury [121]. Spondin 1 is also a 
chemoattractant that promotes correct “pathfinding” of commissural axons which cross 
the floorplate [135].  
Cleavage of Spondin 1 into smaller polypeptides also plays a role in signalling. In 
HEK293 (human embryonic kidney) but not COS (green monkey kidney) cells 
(suggesting a cell type-dependent process), Spondin 1 is cleaved into two half proteins, 
with the reeler and spondin domains in one half and the TSRs in the other [121]. The 
TSRs can also be cleaved between the fourth and fifth repeats [121]. This cleavage is 
achieved by plasmin and releases the more N-terminal part of the protein from the ECM 
as the fifth and sixth TSRs bind the ECM but TSRs 1-4 do not [136]. The TSR half of the 
protein is responsible for commissural axon guidance [137], while the reeler/spondin half 
is responsible for outgrowth [121]. Further study of the two TSR fragments shows that 
the 5-6 fragment remains at the basement membrane and the 1-4 fragment localizes to the 
cell surface of the floorplate where it is tethered by its interaction with apolipoprotein E 
receptor 2, ApoER2, also known as low-density lipoprotein receptor 8, LRP8, and other 
low-density lipoprotein receptor proteins, LDLRs [137]. Surprisingly, the Spondin 1-like 
protein Reelin also associates with LRP8 and other lipoprotein receptors, although it does 
not contain TSRs, suggesting that the reeler domain may still play a functional role in this 
interaction. The TSR 1-4 fragment inhibits growth of commissural axons into the 
floorplate while the 5-6 fragment promotes outgrowth below the floorplate [137]. Motor 
neuron outgrowth is also affected by Spondin 1 in a contact-repellent manner in vitro and 
again the TSR region was found to be more important than the N-terminal half of the 
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protein for this effect [138]. Spondin 1 also acts as a repellent molecule in the caudal half 
of somites in chicken embryos where it inhibits the migration of neural crest cells [139].  
Spondin 1 not only affects nerve growth and adhesion but promotes nerve cell 
differentiation and viability as well. In a rat adult hippocampal precursor cell line, AHP, 
treatment with Spondin 1 promoted differentiation from neural precursor to nerve-like 
cells and this function was attributed to the reeler/spondin domains rather than the TSRs 
[140]. Spondin 1 increases the viability of chicken ciliary ganglion (CG) cell in culture 
via the activation of TGF-β signalling by the sixth TSR via its KRFK motif [141]. 
However, loss of the reeler and spondin domains resulted in decreased CG survival while 
reeler, spondin, and the sixth TSR without TSRs 1-5 was sufficient to maintain survival, 
suggesting that although the KRFK motif activates TGFβ, the reeler and spondin domains 
are required for complete signalling [141]. This increased survival was also a result of 
increased disabled-1 (DAB-1) signalling achieved through interaction with the amyloid 
precursor protein (APP) receptor [141].   
In summary, within the nervous system, Spondin 1 regulates cell adhesion, nerve 
outgrowth, axon guidance, cell viability and differentiation and as a whole protein and as 
cleavage products is an attractant and repellent molecule as well as being involved in cell 
signalling. 
1.2.3 Other Functions and Mechanisms of Action 
The known functions of Spondin 1 outside of the nervous system are similar to 
those within it. Spondin 1 that was isolated and purified from bovine follicular fluid 
promoted growth of rat aortic vascular smooth muscle cells in vitro [115]. However, 
Spondin 1 also inhibits vascular endothelial growth factor (VEGF)-stimulated migration 
and tube formation of human umbilical vein endothelial cells (HUVECs) as well as 
neovascularization within the rat cornea [142]. Inhibition of HUVEC migration may 
result from blocked signalling of integrin αvβ3 and decreased activation of AKT [142]. 
Interestingly, Spondin 1 has been implicated in both promoting and inhibiting 
angiogenesis and therefore it is possible that different domains and locations of the 
protein may play a role as previously identified in nerve outgrowth. These seemingly 
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opposed actions may indicate that Spondin 1 is involved in guiding or limiting growth of 
new blood vessels. 
Cell adhesion in neural and non-neural tissues in C. elegans is affected by 
Spondin 1 [143]. Spondin 1 localizes to integrin expressing regions and basement 
membranes in the C. elegans embryo and mutants with a defective Spondin 1 lose 
attachment of muscle to the epidermis along with loss of cell adhesion in axons [143]. 
As mentioned in 1.2.2, Spondin 1 interacts with LDLRs, specifically LRP8 and 
VLDLR. It also interacts with amyloid precursor protein, APP. β-secretase cleavage of 
APP results in Aβ products whose accumulation is associated with Alzheimer’s disease. 
However, APP interaction with Spondin 1 creates a complex of APP, Spondin 1, and 
LRP8 that results in decreased production of Aβ cleavage products [144, 145], making 
Spondin 1 an intriguing target for Alzheimer’s therapeutics. 
Studies with chicken ciliary ganglion suggest a role for Spondin 1 in cell survival 
(see 1.2.2). Further evidence of this function is seen in murine neuroblastoma cells, 
Neuro-2a, when exposed to adverse conditions [146]. Knockdown of Spondin 1 in these 
cells results in decreased levels of interleukin-6 (IL-6), and decreased survival after 
serum starvation or Aβ-peptide treatment. This decrease in IL-6 was correlated with 
decreases in NF-κB and p38 mitogen-activated protein kinase (MAPK) [146]. Treatment 
with Spondin 1 or IL-6 rescues cell survival. This suggests that not only does Spondin 1 
inhibit cleavage of APP but also reduces the effects of Aβ peptides. 
Alterations in TGFβ signalling due to Spondin 1, also seen in chicken ciliary 
ganglion cells , was first observed in chondrocytes in osteoarthritic cartilage in vitro 
[147]. Increased activation of latent TGFβ results in increased expression of matrix 
metalloproteinase 13 (MMP-13), and prostaglandin E2 (PGE2) leading to increased 
collagen degradation and decreased  proteoglycan synthesis [147]. In embryonic cartilage 
Spondin 1 is highly expressed and via TGFβ induces chondrocyte maturation and 
mineralization by increasing MMP-13 and alkaline phosphatase (AP) expression [148].  
These two proteins are also upregulated by Spondin 1 during cementoblast differentiation 
[149]. The only paper to date that studies the Spondin 1 knockout mouse addresses the 
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effect of Spondin 1 loss in bone and cartilage. At six months of age, these mice have 
increased bone mass most likely due to elevated bone synthesis. Levels of TGFβ1 are 
decreased in serum while the levels of phosphorylated SMAD1/5, bone morphogenetic 
protein (BMP) regulatory SMADs, is increased. The authors hypothesize that decreased 
TGFβ signalling leads to increased BMP signalling and bone deposition in adult mice 
[150]. 
Outside of the nervous system, Spondin 1’s functions and mechanisms are 
analogous to those within. The effects on angiogenesis in other tissues are similar to 
those seen in outgrowth of nerves. As in the nervous system, cell adhesion is lost with 
loss of Spondin 1 in muscle. Cell survival and differentiation are affected in 
neuroblastoma and cartilage, respectively, and both Spondin 1-regulated TGFβ and LRP8 
signalling are also observed outside of the CNS.  
1.2.4 Spondin 1 and the Ovary 
  Evidence for a role of Spondin 1 in the ovary is sparse but compelling. First, 
Spon1 gene expression increases in the uterus and mammary gland of ovariectomized 
mice treated with 17β-estradiol [151, 152]. Spon1 expression is decreased 2.5-fold in 
granulosa cells of eCG-treated estrogen receptor β (ERβ) knockout mice compared to 
eCG-treated mice heterozygous for ERβ [153]. Second, as mentioned in 1.2.3, Spondin 1 
was isolated and purified from bovine follicular fluid and robustly promoted the growth 
of vascular smooth muscle cells, suggesting a role in the ovary in angiogenesis or 
vascularization [115]. A role for Spondin 1 in angiogenesis in the ovary is further 
indicated by the fact that Spondin 1 is expressed in the boar testis during development 
when vascularization and angiogenesis are occurring but is not expressed post-puberty 
[154].  
 Spondin 1 is highly expressed in ovarian cancer and is considered to be a 
biomarker for the disease [155]. Positive expression of Spondin 1 may be a negative 
prognostic indicator and its expression is higher in late stage ovarian cancer versus early 
stage [156]. No work has been done to determine what role Spondin 1 may play in 
oncogenesis or progression of ovarian cancer; however, the increased survival of 
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neuroblastoma cells in the presence of Spondin 1 may suggest that it plays a similar role 
in ovarian cancer cells [146]. 
1.3 Rationale 
Since Spondin 1 was first identified in 1992, its functional and mechanistic roles 
in nerve outgrowth, cell adhesion, cell survival, cell differentiation, and angiogenesis 
have been studied in various tissues, both within the nervous system and several tissues 
without. However, its role in the ovary has never been characterized, despite evidence 
that i) it is present in the ovary, ii) it may be an ovarian factor for angiogenesis, iii) its 
mRNA expression is regulated by 17β-estradiol, and iv) it is highly overexpressed in 
ovarian cancer. If Spondin 1 is functional within the ovary it is likely to act in the same 
manner as in other tissues. Therefore, it could function in cell survival or proliferation, 
cell differentiation, angiogenesis, or cell adhesion/migration during the process of 
folliculogenesis. The discovery of a role for Spondin 1 in the ovary could have 
implications in the fields of infertility and ovarian cancer.   
1.4 Hypothesis and Objectives 
      The work presented in this thesis was executed to test the hypothesis that Spondin 1 
plays a functional role in ovarian folliculogenesis. 
To test this hypothesis I pursued the following objectives: 
1) To characterize functions of Spondin 1 in granulosa cell tumour cell lines to discover 
roles for Spondin 1 in granulosa cells and possibly ovarian cancer. 
2) To characterize expression and functions of Spondin 1 in mouse primary granulosa 
cells and the mouse ovary to discover the possible role of Spondin 1 in ovarian 
folliculogenesis. 
3) To characterize the reproductive phenotype of the Spon1-/- female mouse to determine 
if loss of Spondin 1 affects fertility. 
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2 Chapter 2 – Spondin 1 regulates steroidogenesis and 
viability in granulosa cell lines 
This chapter is based on a manuscript submitted to the Journal of Reproduction and 
Development. 
O’Flynn, C, Pampillo, M, Deroo, BJ. (2015) The extracellular matrix protein, Spondin 1, 
regulates human granulosa cell steroidogenesis and viability. Manuscript ID# JRD-2015-
066. Under revision. 
2.1 Introduction 
Folliculogenesis is the process whereby immature primordial follicles develop 
into mature preovulatory follicles capable of releasing a mature oocyte. This process is 
complex, and tightly-regulated by a variety of signals, both extra- and intra-ovarian, as 
well as extracellular and intracellular. These signals include, but are not limited to 
gonadotropins, steroid hormones, growth factors, peptides, miRNAs, and extracellular 
matrix (ECM) proteins. While these and other factors regulating folliculogenesis have 
been identified, due to its complexity, the factors responsible for successful 
folliculogenesis are not yet fully understood. However, identifying these factors and their 
functions is critical for understanding and treating infertility resulting from defects in 
folliculogenesis and ovulation.  
The majority of folliculogenesis intra-ovarian factors identified to date are oocyte-
derived factors that regulate granulosa cell or cumulus cell function. Less work has been 
undertaken regarding somatic-cell derived factors [1]. Known examples of major 
granulosa cell-derived secreted factors essential for follicle development include Anti-
Müllerian hormone (AMH), inhibins and activins, activin-binding-protein (follistatin), 
prostaglandins, and the wingless-type MMTV integration site family (WNT), bone 
morphogenetic protein (BMP), and epidermal growth factor (EGF) families of proteins. 
However, despite the growing body of knowledge indicating that in many tissues, the 
ECM provides not only structural support to the cells it surrounds, but initiates signal 
transduction pathways in the same cells [2, 3], little is known about how signalling by 
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ECM proteins to ovarian cells contributes to folliculogenesis. In this study, we examine 
F-Spondin/Spondin 1, hereafter referred to as SPON1, an ECM protein that is present 
within granulosa cells of the human and mouse ovary, but whose function within the 
ovary remains unknown.  
SPON1, encoded by SPON1, is a secreted glycoprotein that was originally 
identified in, and studied for its role in, the central nervous system (CNS). SPON1 is a 
member of the thrombospondin family, and contains six C-terminal thrombospondin 
repeats (TSRs), an N-terminal reeler domain, and a spondin domain [4, 5]. The reeler 
domain (aa 1-200) is homologous with a domain in the protein, Reelin (RELN), which, 
like SPON1, regulates neuronal migration [4, 6]. The spondin domain (aa 201-440) is 
homologous with regions in Spondin 2, proteins known to bind the ECM [4, 6]. In the 
CNS, SPON1 promotes the outgrowth of embryonic hippocampal neurons [6] and the 
outgrowth of sensory neurons in peripheral nerves after injury, but inhibits outgrowth of 
embryonic motor neurons by contact repulsion [7]. SPON1 is required for pathfinding of 
commissural axons [6] and is a signalling molecule for segmentation of neural crest cells 
in somites [8]. SPON1 induces both morphological and biochemical differentiation of 
CNS precursor cells into nerve cells [9].  
SPON1 also carries out similar functions in other tissues. In C. elegans, SPON1 
localizes to integrin-containing tissues, body muscle, and basement membranes, and 
functions via integrins to maintain ECM adhesion [10]. SPON1 promotes growth of 
vascular smooth muscle cells [11] and increases cell survival of murine neuroblastoma 
[12] and chicken ganglion cells [13]. SPON1 also promotes chondrocyte terminal 
differentiation [14], cementoblast (HCEM, human cementoblast-like cell line) 
differentiation [15], and inhibits osteoclast differentiation [16]. Finally SPON1 inhibits 
migration of HUVECs [17] and human cementoblast-like (HCEM) cells [15]. Thus, 
SPON1 regulates adhesion, outgrowth, differentiation, proliferation, migration and 
viability in many different tissues and species. 
SPON1 is highly expressed in the human ovary relative to other human tissues 
[11], is overexpressed in ovarian cancer [18], and is currently under investigation as a 
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new marker for detection of ovarian cancer [18-20]. However, the biological function of 
SPON1 in the ovary is currently unknown. A potential functional role for SPON1 in 
granulosa cells of the ovary is supported by several intriguing lines of evidence. First, 
SPON1 isolated from bovine follicular fluid increases proliferation of endothelial cells 
[17]. Secondly, in primary rat granulosa cells, SPON1 is regulated by follicle-stimulating 
hormone (FSH) [21]. FSH and a constitutively-active protein kinase A (PKA) mutant 
increase Spon1 mRNA levels 3-fold and 4-fold, respectively in this model [21]. 
Interestingly, the secreted ECM glycoprotein, thrombospondin-1 (TSP-1/THBS1), is 
produced by granulosa cells and regulates ovarian angiogenesis in various species [22]. 
Thus, although compelling evidence suggests that SPON1 may play a role during 
folliculogenesis by regulating granulosa cell function and may be involved in ovarian 
cancer progression, little is known about SPON1’s functional role within granulosa cells 
of the ovary. 
Therefore, to test the hypothesis that SPON1 regulates granulosa cell function, we 
examined the effect of exogeneous recombinant human SPON1 on the steroidogenesis, 
viability, and proliferation of the metastatic human granulosa cell tumor-derived cell line, 
KGN. We also carried out a screen to identify potential signalling pathways involved in 
SPON1’s effect on human granulosa cell function. 
2.2 Materials and Methods 
2.2.1 Cell Culture 
The metastatic human granulosa cell tumor-derived cell line, KGN, was kindly 
provided by Drs. T. Yanase and Y. Nishi [23] via the RIKEN BRC through the National 
Bio-Resource Project of the MEXT, Japan. KK-1 granulosa cells were derived from a 
tumor in a transgenic mouse expressing the Simian Virus 40 (SV40) T antigen under the 
control of the mouse inhibin α-subunit promoter [24], and kindly provided by Dr. 
Douglas Stocco (Texas Tech University Health Sciences Center). Both KGN and KK-1 
cell lines were maintained in Dulbecco Modified Eagle medium: Nutrient Mixture F-12 
(DMEM/F12) (Wisent Inc.) supplemented with 10% fetal bovine serum (FBS) (Wisent) 
and 1% Penicillin/Streptomycin (Pen/Strep) with 1 mM glutamine (Wisent) and 
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maintained in 5% CO2  at 37C. Huh-7 cells, a human hepatoma line, were kindly 
provided by Jason Matthews (The University of Toronto, Toronto, ON) and cultured in 
Dulbecco Modified Eagle medium (DMEM) supplemented with 10% FBS, 1% 
Pen/Strep, and 1 mM glutamine. Huh-7 cells were maintained in 5% CO2 at 37C. Both 
granulosa cell lines were initially treated with both 1 μg/ml and 5 μg/ml recombinant 
human SPON1 (SPON1) (R&D Systems, made is a mouse cell line and contains a His-
tag); however only 5 μg/ml treatment resulted in a significant increase in viability 
compared to vehicle-treated cells, and thus 5 μg/ml was used for all subsequent 
experiments. These doses are comparable to those in other studies in which recombinant 
SPON1 is used to treat cell lines. SPON1 doses range from 0.5 μg/ml [14, 16] to 10 
μg/ml [12]. Ovarian antral and/or circulating concentrations of SPON1 in humans or mice 
are currently unknown. 
2.2.2 Western blots: Human and mouse tissues and cell lines 
To determine SPON1 protein levels in human tissues, Human INSTA-Blot 
membranes were purchased from EMD Millipore (product no. 407211-1BLOT), and 
incubated with a rabbit polyclonal anti-SPON1 antibody (2 g/ml) (product no. ab40797; 
Abcam) for one hour. After incubation for one hour with an anti-rabbit horseradish 
peroxidase (HRP)-conjugated secondary antibody (1:10,000) (product no. 934; GE 
Healthcare, NA), SPON1 levels were visualized with Pierce ECL Plus Western Blotting 
Substrate (Fisher). To determine SPON1 protein levels in mouse tissues, Mouse INSTA-
Blot membranes were purchased from Novus Biologicals Canada (product no. NBP2-
30111) and incubated under the same conditions used for the Human INSTA-Blot. Both 
INSTA-Blots are received pre-stained with amido black, which served as a loading 
control.  
To determine SPON1 levels in the following cell lines: GFSHR-17 (rat 
granulosa), KGN (human granulosa cell tumour), KK-1 (mouse granulosa), SKOV3 
(human ovarian adenocarcinoma), HEC-1 (human endometrial adenocarcinoma), MCF7 
(human mammary adenocarcinoma) and U2OS (human osteosarcoma), cells were 
cultured in DMEM/F12 supplemented with 5% FBS, 1% Pen/Strep, and 1 mM glutamine 
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(GFHSR-17), DMEM/F12 supplemented with 10% FBS and 1% Pen/Strep with 1 mM 
glutamine (KGN, KK-1), DMEM (Wisent) supplemented with 5% FBS and 1% 
Pen/Strep with glutamine (SKOV3), DMEM supplemented with 10% FBS and 1% 
Pen/Strep with 1 mM glutamine (HEC1, MCF7, U2OS). The GFSHR-17 cell line [25] is 
an immortalized gonadotropin-responsive rat granulosa cell line that we obtained from 
Dr. Abraham Amsterdam (Weizmann Institute of Science). The SKOV3 cell line was 
graciously provided by Dr. Gabriel DiMattia (Lawson Health Research Institute, London, 
ON). The HEC-1 cell line was purchased from the ATCC (American Type Culture 
Collection). The MCF7 cell line was kindly provided by Dr. Joseph Torchia (Lawson 
Health Research Institute, London, ON). The U2OS cell line was obtained from Dr. 
Frederick Dick (University of Western Ontario). 
Protein lysates were prepared using Radioimmunoprecipitation assay buffer 
(RIPA, 150 mM sodium chloride, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% 
sodium dodecyl sulphate, 50 mM Tris, pH 8.0) and lysate concentrations were measured 
using the DC protein assay (Bio-Rad Laboratories (Canada) Ltd). Proteins were separated 
by SDS-PAGE and transferred to a polyvinylidene difluoride (PVDF) membrane. 
Membranes were incubated with SPON1 antibody under the same conditions used for the 
INSTA-Blot membranes. Immunizing peptide blocking experiments were carried out 
using the blocking peptide provided by the manufacturer (product no. ab41539, Abcam) 
for the SPON1 primary antibody we used. -tubulin was used as a loading control. 
2.2.3 Progesterone Assay  
KGN cells were plated at 80 000 cells per well into a 24-well plate in DMEM/F12 
supplemented with charcoal stripped FBS (Wisent). After 24 hours, cells were treated 
with bovine serum albumin (BSA) control (250 μg/mL; BioShop Canada Inc.), 
recombinant human SPON1 (SPON1) (5 g/mL; R&D Systems, Minneapolis, MN), 
dibutyryl-cAMP (dbcAMP) (1 mM) (Enzo Life Sciences), or both SPON1 (5 g/mL) and 
dbcAMP (1 mM). Media was removed after 48 hours and frozen at -80C until further 
analysis. Protein lysates were prepared using RIPA buffer supplemented with a protease 
inhibitor cocktail  (1:1000 dilution, product no. P8340-5ml; Sigma). Protein lysate 
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concentrations were determined using the DC protein assay (Bio-Rad). Cell culture media 
was sent to the University of Virginia Centre for Research in Reproduction Ligand Assay 
and Analysis Core (Charlottesville, VA) and the progesterone concentration determined 
by progesterone radioimmunoassay (RIA). Progesterone concentrations were calculated 
by normalizing ng/μl progesterone/well to the total protein/well. Differences in 
progesterone levels between the four treatments, ie. vehicle, dbcAMP, SPON1, or 
dbcAMP + SPON1 were analyzed by one-way analysis of variance (ANOVA) followed 
by a Tukey Multiple Comparison post-hoc test (Tukey test) (PRISM 6.0e for Mac OSX; 
GraphPad). 
2.2.4 Quantitative RT-PCR  
KGN cells were seeded into six-well plates and treated as for progesterone assays. 
RNA was extracted using the Qiagen RNeasy mini kit, the second step of which requires 
the Qiashredder kit (product nos. 74104 and 79654, respectively; Qiagen). RNA was 
reverse transcribed using Superscript II reverse transcriptase (Life Technologies). 
Relative gene expression levels were determined using TaqMan Fast Advanced Master 
Mix (product no. 4444963; Life Technologies) and TaqMan probe sets in 384-well plates 
with a final reaction volume of 10 µl/well. cDNA levels were detected by quantitative 
PCR using the Applied Biosystems 7900HT Fast Real Time PCR System. TaqMan Gene 
Expression Assays (product no. 4331182; Life Technologies) probe/primer sets were 
used to analyze CYP11A1, STAR, CYP17A1, CYP19A1, HSD3B1, HSD17B1, HSD17B3, 
and RPL7 (endogenous control). Fold changes in gene expression were determined by 
quantitation of cDNA from target (treated) samples relative to a calibrator sample 
(vehicle). The gene for ribosomal protein L7 (RPL7) was used as the endogenous control 
for normalization of RNA levels.  Expression ratios were calculated using the CT 
model. Data averaged from three independent experiments were analyzed by one-way 
ANOVA followed by a Tukey multiple comparison post-hoc test, with the exception of 
STAR, for which a single representative experiment is shown. The reason a single 
representative experiment is shown for STAR is that although SPON1 significantly 
reduced dbcAMP-induced STAR mRNA levels in each of three independent experiments 
(data not shown), when the data from all three experiments were combined, this effect of 
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SPON1 was no longer statistically significant. We believe this variability between 
experiments is largely due to the variable response of the KGN cell line to dbcAMP. All 
data was analyzed using PRISM 6.0e for Mac OSX; GraphPad. 
2.2.5 Western blot: STAR expression in SPON1-treated KGN cells  
To determine SPON1’s effect on steroidogenic acute regulatory protein (STAR) 
expression in KGN cells, cells were plated into six-well dishes in DMEM/F12 
supplemented with 10% charcoal stripped FBS, incubated for 24 hours, then treated with 
dibutyryl-cAMP (dbcAMP) (1mM) (Enzo Life Sciences, Inc.) or both SPON1 and 
dbcAMP for 8 or 24 hours. Protein lysates were prepared using RIPA buffer and protein 
concentrations were measured using a DC Protein assay (Bio-Rad). Proteins were 
separated using SDS-PAGE and transferred to PVDF membrane for 2 hours at 100V at 
4°C. The membrane was blocked in 5% milk in TBST (50 mM Tris-HCl, 150 mM NaCl, 
0.1% Tween 20) and incubated in STAR primary antibody (1:500 dilution; product no. 
sc-25806; Santa Cruz) overnight at 4°C, then incubated with anti-rabbit HRP-conjugated 
secondary (1:10 000 dilution, product no. NA 934; GE Healthcare) for 1 hour at room 
temperature (rt). -tubulin was used as a loading control; -tubulin antibody (1:8000 
dilution, product no. T5168; Sigma) and anti-mouse HRP conjugated (1:10 000 dilution, 
product no. NA 931; GE Healthcare) were applied to the membrane under the same 
conditions used for the STAR Western blot. STAR: -tubulin ratios were calculated 
using ImageJ software [26]. 
2.2.6 STAR Promoter Luciferase Assays 
A STAR promoter reporter plasmid (STAR-luc) containing 966 bp of the STAR 
proximal promoter driving firefly luciferase expression on a pGL3 backbone was kindly 
provided by Dr. Douglas Stocco (Texas Tech University Health Sciences Center). 
Luciferase assays were carried out using Huh-7 cells (a human liver hepatoma cell line). 
Huh-7 cells were seeded into 24-well plates at 60 000 cells/well in DMEM supplemented 
with 10% charcoal stripped FBS, 1% Pen/Strep and 1 mM glutamine. After twenty-four 
hours, the cells were transfected with STAR-luc (250 ng/well), a Renilla luciferase 
control plasmid pRL-TK (20 ng/well), and pcDNA3 (230 ng) at a 1:3 ratio with FuGENE 
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HD (product no. PRE 2311; Fisher) (500 ng DNA: 1.5 μl FuGENE HD). DNA and 
FuGENE HD were suspended in antibiotic-free DMEM supplemented with 10% charcoal 
stripped FBS. Twenty-four hours after transfection, the cells were treated with SPON1 
(5 μg/ml), 8-CPT-cAMP (2.5 mM, product no. BML-CN130; Enzo Life Sciences), or 
both. Forty-eight hours after treatment, STAR promoter activity was assessed using the 
Promega Dual Luciferase Reporter Assay System (product no. E1960; Fisher). 
Differences in firefly/Renilla luciferase ratios between vehicle treatment alone or 
treatment with SPON1 were analyzed by a two-tailed, unpaired, Student’s t-test (PRISM 
6.0e for Mac OSX; GraphPad). 
2.2.7 Cell Viability Assays and Cell Counting 
KGN and KK-1 cells were seeded at 5000 cells per well into 96-well plates, 
incubated for one hour, then treated with recombinant human SPON1. Cell viability was 
measured after 24, 48, and 72 hours using the Cell Titer AQueous Non-Radioactive Cell 
Proliferation Assay (MTS) (product no. PRG3582; Promega). Cell counts were measured 
at 24, 48, and 72 hours by trypsinizing the cells, then counting an aliquot of the 
trypsinized cells using a Coulter counter.  Differences in viability and cell number 
between vehicle treatment alone or treatment with SPON1 at each time-point were 
analyzed by a two-tailed, unpaired, Student’s t-test (PRISM 6.0e for Mac OSX; 
GraphPad). 
2.2.8 Phospho-kinase Arrays and PRAS40 phosphorylation 
Western blot 
To screen for potential downstream targets of SPON1 that may act in the signal 
transduction pathways regulating granulosa cell function in response to SPON1, a 
Proteome Profiler Human Phospho-kinase array was purchased from R&D Systems 
(product no. ARY003B). This array allows for the simultaneous analysis of the relative 
site-specific phosphorylation levels of 43 different kinase proteins or their targets.  KGN 
cells were grown as described (see section 2.2.1) in a 10 cm dish and the media replaced 
three hours prior to treatment with serum-free medium. Cells were then treated with BSA 
(250 μg/ml; Bioshop) or SPON1 (5 μg/ml) for 15 minutes. This time-point was chosen 
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based on published studies [12, 13] in which recombinant SPON1 is applied to cultured 
cells and SPON1-induced kinase activation is detected (10 to 30 minutes). For the 
phospho-kinase array, 400 μg of protein was applied to the blots.  
To confirm the SPON1-induced increase in proline-rich AKT1 substrate 1  
(PRAS40/AKT1S1) levels that we observed in the phospho-kinase array (see Phospho-
kinase Methods section), KGN cells were plated into six-well plates, incubated for 24 
hours, then serum-starved for three hours. The cells were then treated with SPON1 (5 
μg/ml) or BSA (vehicle control) (250 μg/ml; Bioshop) for 0, 15, or 60 minutes. Protein 
lysates were prepared using RIPA buffer supplemented with protease and phosphatase 
inhibitors (1:10 000 dilution, product no. P2850-1 mL; Sigma) and protein concentrations 
were measured using the DC protein assay (Bio-Rad). Proteins were separated using 
SDS-PAGE and transferred to a PVDF membrane for 2 hours at 100V at 4°C. The 
membrane was blocked in 5% BSA in TBST and incubated in pPRAS40 antibody (1 
μg/ml, product no. 2640S; Cell Signalling technology, Inc.) overnight at 4°C, followed 
by incubation with anti-mouse HRP conjugated (1:10 000 dilution, product no. NA 931; 
GE Healthcare) for 1 hour at rt. Total PRAS40 levels were determined using a second 
Western blot onto which the same amount of lysate was loaded as for the pPRAS40 blot. 
The resulting membranes were incubated with PRAS40 antibody (0.5 μg/ml, product no. 
2610; Cell Signalling Technology, Inc.) overnight at 4°C. Histone deacetylase 4 
(HDAC4) was used as a loading control; HDAC4 antibody (1:1000 dilution, product no. 
sc-11418; Santa Cruz), followed by incubation with anti-rabbit HRP conjugated 
(1:10 000 dilution, product no. NA 934; GE Healthcare) incubated under the same 
conditions used for the PRAS40 Western blots.  
2.3 Results  
2.3.1 SPON1 expression in human and mouse tissues and cell 
lines 
Because little is known about SPON1 protein levels in human and mouse tissues 
and granulosa cells, we first investigated SPON1 levels in these models. We found that  
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Figure 2-1. SPON1 expression in human and mouse tissues and immortalized cell 
lines. 
A. A human tissue INSTA-Blot™ was incubated with an anti-Spondin 1 antibody to 
detect SPON1 (arrow, upper). Lanes: 1) Brain; 2) Heart; 3) Small Intestine; 4) Kidney; 5) 
Liver; 6) Lung; 7) Muscle; 8) Stomach; 9) Spleen; 10) Ovary; 11) Testis. Amido black 
staining as a control (bottom). B. A mouse tissue INSTA-Blot™ was incubated with an 
anti-SPON1 antibody to detect SPON1 (arrow, upper). Lanes: 1) Brain; 2) Heart; 3) 
Small Intestine; 4) Kidney; 5) Liver; 6) Lung; 7) Muscle; 8) Stomach; 9) Spleen; 10) 
Ovary; 11) Testis. Amido black staining as a control (bottom). C. SPON1 expression in a 
panel of reproductive or estrogen-responsive mouse and human immortalized cell lines. 
Lanes: 1) Rat GFSHR-17 granulosa cell line; 2) Human KGN human granulosa cell 
tumor cell line; 3) Mouse KK-1 granulosa cell line; 4) Human SKOV3 ovarian cancer 
cell line; 5) Human HEC1 endometrial carcinoma cell line; 6) Human MCF7 breast 
cancer cell line; 7) Human U2OS osteosarcoma cell line. -tubulin was used as a loading 
control (bottom). 
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SPON1 expression was similar in most human and mouse tissues, with a few notable 
differences (Fig. 2-1). In human tissues (Fig. 2-1 A), SPON1 (arrow) was most highly 
expressed in the ovary and testis, with robust expression also in brain, heart, small 
intestine, and liver. Weaker expression was observed in kidney, lung, skeletal muscle, 
and stomach. In mouse tissues (Fig. 2-1 B), SPON1 was most highly expressed in the 
brain, heart, kidney, muscle, spleen, ovary, and testis. Comparing human and mouse 
SPON1 tissue expression, the main difference was that SPON1 was easily detectable in 
human small intestine, liver, and lung, but only weakly expressed in these tissues in the 
mouse (Fig. 2- 1 A and B). Conversely, in mouse tissues, SPON1 was easily detectable 
in kidney and spleen, but barely detectable in these human tissues. We also detected 
SPON1 in a variety of different granulosa cell lines and cell lines of other reproductive 
tissue origin (Fig. 2-1 C). These included the GFSHR-17 cell line (an immortalized 
gonadotropin-responsive rat granulosa cell line) [16, 25], the human granulosa cell-like 
cell line, KGN [17, 23], the KK-1 cell line, an immortalized mouse ovarian granulosa 
tumor cell line [24], HEC-1 endometrial adenocarcinoma cells, MCF7 breast cancer 
cells, SKOV3 ovarian cancer cells, and U2OS osteosarcoma cells (a non-reproductive 
cell type). SPON1 was robustly expressed in all cell lines (Fig. 2-1 C), with the greatest 
expression in the granulosa and ovarian cancer cell lines (Lanes 1-4). Immunizing 
peptide blocking experiments confirmed that this binding was specific (data not shown).  
2.3.2 SPON1 reduces progesterone levels in response to cAMP 
stimulation of KGN cells 
We next investigated whether SPON1 would affect one of the primary functions 
of granulosa cells: steroidogenesis. KGN cells produce progesterone in response to 
stimulation by cAMP and therefore are a good model to study progesterone production; 
however, they do not produce significant levels of 17β-estradiol. Therefore, we did not 
measure 17β-estradiol levels. We treated KGN cells with the cAMP analog, dbcAMP, in 
the presence or absence of SPON1 and measured progesterone levels in the media after 
48 hours. cAMP treatment increased progesterone levels 5.3-fold over vehicle-treated 
KGN cells (Fig. 2-2), while SPON1 treatment alone had no significant effect. However,  
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Figure 2-2. SPON1 inhibits the cAMP-mediated increase in progesterone levels in 
KGN cells. 
Cells were treated for 48 hours with vehicle, dbcAMP (1 mM), SPON1 (5 g/mL), or 
dbcAMP (1 mM) + SPON1 (5 g/mL). Progesterone levels in the culture media were 
determined by radioimmunoassay and normalized to total protein levels. Data are 
expressed as average progesterone levels in KGN medium (± SEM of three independent 
experiments). Differences in progesterone levels between the four treatments, ie. vehicle, 
dbcAMP, SPON1, or dbcAMP + SPON1were analyzed by a one-way ANOVA followed 
by a Tukey Multiple Comparison post-hoc test (Tukey test). There was a statistically 
significant difference between the four treatments as determined by one-way ANOVA, F 
(3, 8) = 120, P < 0.0001. A Tukey test revealed that there were statistically significant 
differences (P < 0.05) between: vehicle and dbcAMP; vehicle and dbcAMP + SPON1; 
dbcAMP and SPON1; dbcAMP and dbcAMP + SPON1; SPON1 and dbcAMP + SPON1. 
a = P < 0.05. n=3. 
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SPON1 reduced the cAMP-mediated increase in progesterone from 5.3-fold to 3.3 fold; a 
reduction of 38%. 
2.3.3 SPON1 inhibits the cAMP-induced expression of CYP11A1, 
CYP17A1 and STAR in KGN cells 
To determine if SPON1 might reduce cAMP-mediated progesterone levels by 
inhibiting the expression of steroidogenic enzymes key to the production of progesterone 
or its conversion to other steroids (see Appendix A – Steroidogenesis Pathway), we 
measured the mRNA levels of CYP11A1, CYP17A1, CYP19A1, HSD3B1, HSD17B1, 
HSD17B3, and STAR (which regulates the rate-limiting step of steroidogenesis by 
regulating cholesterol movement within the mitochondria) in KGN cells. Cells were 
treated with dbcAMP in the presence or absence of SPON1 for 24 hours (Fig. 2-3). 
Interestingly, SPON1 treatment reduced the mRNA levels of both CYP11A1 and 
CYP17A1 by 45% and 40%, respectively (Fig. 2-3 A and C). STAR mRNA levels were 
also significantly reduced by SPON1 (Fig. 2-3 B). However, mRNA levels of CYP19A1 
(Fig. 2-3 D), HSD3B1, HSD17B1, and HSD17B3 (data not shown) were not significantly 
altered following SPON1 treatment. 
Because STAR is upstream of CYP11A1 and CYP17A1, we chose to pursue its 
regulation by SPON1 further. Protein levels of cAMP-induced STAR were significantly 
reduced by SPON1 treatment (Fig. 2-4). After 8 hours of dbcAMP treatment, STAR 
protein levels increased 2.6-fold relative to vehicle, and co-treatment with SPON1 
reduced this by 50% (Fig. 2-4 A and B). After 24 hours of dbcAMP treatment, STAR 
protein levels increased 7.1-fold, and co-treatment with SPON1 reduced this by 89%, 
similar to the vehicle-treated levels of STAR (Fig. 2-4 A and B). 
2.3.4 SPON1 inhibits the cAMP-induced activation of the human 
STAR promoter 
To determine if SPON1 inhibits cAMP-induced STAR promoter activity, we 
carried out a luciferase assay in the Huh-7 human liver hepatoma cell line. Huh-7 cells 
were transfected with a construct containing the firefly luciferase gene driven by 966 bp 
of the human STAR proximal promoter, and a Renilla luciferase control plasmid. The  
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Figure 2-3. SPON1 antagonizes the cAMP-mediated increase in CYP11A1, 
CYP17A1 and STAR mRNA levels, but not CYP19A1 mRNA levels in KGN cells. 
Cells were treated for 24 hours with vehicle, dbcAMP (1 mM), SPON1 (5 g/mL), or 
dbcAMP (1 mM) + SPON1 (5 g/mL), and mRNA levels of (A) CYP11A1, (B) STAR, 
(C) CYP17A1 and (D) CYP19A1 determined by quantitative RT-PCR. mRNA data are 
expressed as average gene expression relative to the RPL7 control (± SEM of three 
independent experiments, except for STAR). A. There was a statistically significant 
difference in CYP11A1 mRNA levels between the four treatments as determined by one-
way ANOVA, F (3, 8) = 26, P < 0.001. A Tukey test revealed that there were statistically 
significant differences (P < 0.05) between: vehicle and dbcAMP; vehicle and dbcAMP + 
SPON1; dbcAMP and SPON1; dbcAMP and dbcAMP + SPON1; SPON1 and dbcAMP + 
SPON1. B. There was a statistically significant difference in STAR mRNA levels between 
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the four treatments as determined by one-way ANOVA, F (3, 4) = 63.7, P < 0.0001. A 
Tukey test revealed that there were statistically significant differences (P < 0.01) 
between: vehicle and dbcAMP; vehicle and dbcAMP + SPON1; dbcAMP and SPON1; 
dbcAMP and dbcAMP + SPON1. One representative experiment is shown for STAR. C. 
There was a statistically significant difference in CYP17A1 mRNA levels between the 
four treatments as determined by one-way ANOVA, F (3, 8) = 1.2, P < 0.0001. A Tukey 
test revealed that there were statistically significant differences (P < 0.05) between: 
vehicle and dbcAMP; vehicle and dbcAMP + SPON1; dbcAMP and SPON1; dbcAMP 
and dbcAMP + SPON1; SPON1 and dbcAMP + SPON1. D. There was no statistically 
significant difference in CYP19A1 mRNA levels between the four treatments as 
determined by one-way ANOVA. 
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Figure 2-4. SPON1 antagonizes the cAMP-induced increase in steroidogenic acute 
regulatory (STAR) protein levels. 
A. KGN cells were plated in DMEM/F12 supplemented with 10% charcoal stripped FBS, 
incubated for 24 hours, then treated with dibutyryl-cAMP (dbcAMP) (1mM) or both 
recombinant human SPON1 (SPON1) and dbcAMP for 8 or 24 hours. Protein lysates 
were separated by SDS-PAGE and STAR protein levels assessed by Western blot 
analysis. -tubulin was used as a loading control. n=2 B. Densitometric analysis of 
Western blot data (ImageJ) showing ratio of STAR: -tubulin. 
 
 
 57 
 
cells were then treated with 8-CPT-cAMP with vehicle or SPON1 for 48 hours, and the 
firefly luciferase activity measured and normalized to Renilla luciferase activity (Fig. 2-
5). Compared to treatment with 8-CPT-cAMP alone, SPON1 modestly but significantly 
reduced this increase in STAR promoter activity by 17% (P < 0.0001). 
 
2.3.5 SPON1 increases granulosa cell viability and proliferation in 
KGN and KK-1 cells 
To determine whether SPON1 might affect GC viability, we treated both KGN 
and KK-1 cells with human recombinant SPON1 or bovine serum albumin (BSA) as 
vehicle for 24, 48, or 72 hours. We measured viability using an MTS assay, which detects 
the activity of NAD(P)H-dependent cellular oxidoreductase enzymes, and serves as a 
quantitative measure of the number of viable cells, not of the proliferation of cells. We 
found that SPON1 modestly, but significantly, increased cell viability in both KGN and 
KK-1 cells (Fig. 2-6 A and B). SPON1 increased KGN cell viability after 24, 48 and 72 
hours by 33%, 20% and 75%, respectively. KK-1 viability increased significantly only 
after 72 hours (32%). To determine if the change in viability in both cell lines was a 
result of increased cellular proliferation, we assessed cell proliferation by counting cells 
under conditions corresponding to the viability assay treatments and time-points (Fig. 2-6 
C and D). We found that the number of KGN cells increased significantly compared to 
controls following SPON1 treatment at 48 and 72 hours by 27% and 32%, respectively. 
The increased viability and proliferation of KGN cells following SPON1 
treatment could also result from decreased apoptosis. In order to determine if apoptosis 
was affected by SPON1 treatment we used a Proteome Profiler Human Apoptosis Array 
Kit to look for changes in apoptosis markers in KGN cells following SPON1 treatment 
under the same conditions used for the viability assays. No differences were observed in 
any apoptosis marker proteins (Appendix B), suggesting SPON1 is unlikely to be 
affecting apoptosis in these cells. 
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Figure 2-5. SPON1 inhibits the cAMP-induced activation of the proximal STAR 
promoter. 
 Huh-7 hepatoma cells were transfected with a STAR promoter luciferase construct 
(STAR-luc) containing 966 bp of the STAR proximal promoter. After 24 hours, the cells 
were treated with SPON1 (5 μg/ml), 8-CPT-cAMP (2.5 mM) or both. Forty-eight hours 
after treatment, STAR promoter activity was assessed using the Promega Dual Luciferase 
Reporter Assay System. Differences in firefly/Renilla luciferase values between vehicle 
treatment alone or treatment with SPON1 were analyzed by a two-tailed, unpaired, 
Student’s t-test. a: P < 0.0001. n=3. 
 
 
 
 
 59 
 
 
 
Figure 2-6. SPON1 increases granulosa cell proliferation and cell viability. 
Assessment of cell viability by MTS assay in KGN (A) and KK-1 (B) granulosa cells in 
the presence or absence of SPON1. Cells were cultured in BSA vehicle or human 
recombinant SPON1 (5 g/mL) as indicated. Each data point represents the mean  SD 
of triplicate measurements within one representative experiment. Differences in viability 
between vehicle treatment alone or treatment with SPON1 at each time-point were 
analyzed by a two-tailed, unpaired, Student’s t-test. a: P < 0.01. Assessment of cell 
number in KGN (A) and KK-1 (B) granulosa cells in the presence or absence of SPON1. 
Cells were cultured in BSA vehicle or human recombinant SPON1 (5 g/mL) for 24 to 
72 hours as indicated. Each data point represents the mean  SD of triplicate 
measurements within one representative experiment. Differences in cell number between 
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vehicle treatment alone or treatment with SPON1 at each time-point were analyzed by a 
two-tailed, unpaired, Student’s t-test. b: P < 0.01 n=3. 
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2.3.6 SPON1 increases pPRAS40 levels in KGN cells 
To screen for potential intracellular targets of SPON1 in GCs that could be responsible 
for increased viability and/or proliferation, we used the Proteome Profiler Human 
Phospho-kinase Array Kit, which simultaneously detects the relative levels of 
phosphorylation of 43 phosphorylation sites on 43 proteins and 2 kinase-related (non-
phosphorylated) total proteins, and/or their targets. KGN cells were serum-starved for 
three hours to reduce background kinase activity, then treated for 15 minutes with vehicle 
or SPON1, after which cell lysates were prepared. These lysates were then applied to the 
Human Phospho-Kinase array, and the blots processed and spot intensities quantified 
according to the manufacturer’s directions. Phosphorylation of two proteins, 
PRAS40/AKT1S1 (T246) and WNK-1 (T60), increased 4-fold and 2-fold, respectively, 
after SPON1 treatment compared to control (Fig. 2-7). Of these two proteins identified by 
this analysis, we chose PRAS40 for further investigation. Proline Rich AKT1 Substrate 
of 40 kDa (PRAS40) (Official name: AKT1 substrate 1 (proline-rich); Official symbol: 
AKT1S1) [27] is a member of the mTORC1 complex, which is associated with increased 
cell growth, proliferation and protein production [27, 28].  
To validate the SPON1-mediated increase in pPRAS40 that we observed in the 
array, we conducted Western blot analysis with lysates from KGN cells serum starved for 
three hours and treated with vehicle or SPON1 for 15 or 60 minutes. After fifteen 
minutes, the ratio of pPRAS40 to total PRAS40 levels increased 2-fold following SPON1 
treatment compared to 15 minutes of control (Fig. 2-8 A and B). Similarly, after 60 
minutes, the ratio of pPRAS40 to total PRAS40 levels increased approximately 3-fold 
following SPON1 treatment compared to 60 minutes of vehicle treatment alone (Fig. 2-8 
A and B). 
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Figure 2-7. SPON1 phospho-kinase targets 
KGN cells were serum starved for three hours and then treated with BSA (as control) or 
Spondin 1. KGN cell lysates were incubated with the phospho-kinase array and the array 
protocol followed. The left two blots were BSA-treated and the right two were Spondin 
1-treated. The top two white boxes represent pPRAS40 and the bottom two represent 
pWNK1. The assay was performed twice with identical results, n=2. 
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Figure 2-8. SPON1 increases protein levels of phosphorylated PRAS40. 
A. KGN cells were serum-starved for three hours, then treated with SPON1 (5μg/ml) or 
BSA (vehicle control) (250 μg/ml) for 0, 15, or 60 minutes. Protein lysates were 
separated using SDS-PAGE and protein levels assessed by Western blot analysis. Histone 
deacetylase 4 (HDAC4) was used as a loading control. B. Densitometric analysis of 
Western blot data showing ratio of pRAS40: total PRAS40 (ImageJ). 
 
 
 
 64 
 
2.4 Discussion  
2.4.1 SPON1: an ECM protein that regulates human granulosa 
cell steroidogenesis 
The ECM is composed of a complex array of glycoproteins, collagens, 
glycosaminoglycans, and proteoglycans. While ECM proteins are well-known for their 
role in providing mechanical and structural support to cells, giving tissues shape and 
strength, a growing body of evidence indicates that a major role for ECM proteins 
includes triggering signalling pathways in the cells they surround [2]. Evidence indicates 
that ECM protein-induced signalling can alter cell function, behaviour, migration, 
proliferation, differentiation, and viability [2]. SPON1 is an example of such a signalling 
ECM protein, and we show that altering steroidogenesis in granulosa cells may be one of 
its functions within the ovary. 
In our study, SPON1 reduced cAMP-induced progesterone levels in KGN cells by 38% -
(Fig. 2-2). The extent of this reduction correlated with the SPON1-mediated reduction of 
cAMP-induced CYP11A1 mRNA levels by 45%, and the reduction of steroidogenic acute 
regulatory protein (STAR) protein expression by 40-89% (Fig. 2-3 and 2-4). STAR 
transfers cholesterol from the outer mitochondrial membrane to the inner, while 
CYP11A1 cleaves the cholesterol side chain to form pregnenolone—the first enzymatic 
reaction in steroidogenesis (Appendix A). The SPON1-mediated reduction of cAMP-
induced CYP11A1 and STAR expression is consistent with the reduction in progesterone 
levels that we observed after SPON1 treatment, given that both CYP11A1 and STAR 
participate in converting cholesterol to pregnenolone (the substrate for progesterone). We 
also observed that SPON1 reduced the cAMP-mediated increase in CYP17A1 mRNA 
levels by 40% (Fig. 2-3). Because CYP17A1 converts pregnenolone and progesterone to 
17-hydroxypregnenolone and 17-hydroxyprogesterone, respectively, a reduction in 
CYP17A1 mRNA levels could be predicted to increase progesterone levels. However, 
there are potential explanations for this not occurring, the simplest being that expression 
of CYP17A1 following dbcAMP + SPON1 treatment is decreased due to a lack of 
progesterone resulting from decreased STAR and CYP11A1 activity. The effect of loss of 
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CYP17A1 on progesterone levels may also be negligible compared to loss of STAR and 
CYP11A1. 
While much remains to be understood about ECM proteins in the ovary, there is 
evidence of their involvement in steroidogenesis. The focimatrix is a specialized ECM 
that is located between granulosa cells and is composed of basal lamina ECM proteins 
[29]. The focimatrix is observed in the follicles of multiple species, including humans 
[29-35]. Expression of focimatrix proteins has been linked with steroidogenesis in the 
bovine ovary [29, 30, 36]. mRNA levels of focimatrix proteins have been highly 
correlated with CYP11A1 mRNA levels, suggesting that focimatrix proteins may 
regulating CYP11A1 expression. [30]. These and other studies [37] have pioneered our 
understanding of how ECM proteins may regulate folliculogenesis by showing that the 
gene expression levels of focimatrix proteins correlate with the expression of 
steroidogenic genes in specific model systems. In our study, we extend and expand these 
previous studies by showing that SPON1 alters the expression of CYP11A1 mRNA levels 
and STAR mRNA protein expression in granulosa cells when SPON1 is added to the 
culture medium of granulosa cell lines.  
2.4.2 Inhibition of cAMP-induced STAR and CYP11A1 expression 
in granulosa cells by other biological molecules  
In addition to SPON1, several other proteins and biological molecules inhibit the 
cAMP-induced increase in STAR mRNA or protein levels. Exogenous bone 
morphogenetic protein 15 (BMP15) inhibits progesterone production in SVOG cells 
(immortalized human granulosa cells) by reducing STAR mRNA and protein levels, and 
this is consistent with the levels of progesterone in the culture medium [38]. A second 
example of a biological molecule that inhibits STAR and CYP11A1 expression is 
cholesterol sulfate (CS) [39], a component of the cell membrane, that inhibits the cAMP-
induced increase in progesterone production and STAR and CYP11A1 mRNA levels in 
KGN cells—the same cells used in our study. STAR protein levels are also reduced by 
CS treatment [39]. However, the mechanism for this reduction was not investigated. 
Finally, in human primary granulosa cells [40], Yamamoto et al. find that oocyte-derived 
growth differentiation factor 9 (GDF-9) inhibits the cAMP-mediated increase in the 
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mRNA levels of STAR, CYP11A1, and CYP19A1. Because all three genes are affected, 
the authors propose that GDF-9 must block a key step in the cAMP-dependent/PKA 
pathway [40]. Thus, SPON1 can now be added to the short list of factors that inhibit the 
increase of STAR and CYP11A1 by cAMP; however, SPON1 is unique among these 
examples because it is an ECM protein, while the others are not. It should be noted that at 
least one study has demonstrated that ECM proteins can regulate STAR expression in 
granulosa cells, although the inhibition of cAMP was not shown [37].  
2.4.3 SPON1 regulation of the human STAR promoter 
To understand how SPON1 might regulate STAR mRNA levels, we postulated 
that SPON1 might, through an unknown mechanism, regulate the STAR promoter. We 
chose to use Huh-7 cells for these experiments after many unsuccessful attempts to 
transfect the KGN and KK-1 cell lines, which are generally considered very difficult to 
transfect. In addition, Huh-7 cells are cAMP-responsive [41-45], and thus we considered 
them a good model to study STAR promoter activity.  We observed a modest (17%), but 
significant, reduction in cAMP-induced STAR promoter activity by SPON1. cAMP is the 
predominant regulator of the STAR gene in the adrenals and gonads [46]. While multiple 
transcription factors and signalling pathways have been identified that regulate STAR 
transcription (see Manna et al. [46] and Stocco et al. [47] for excellent reviews), the exact 
mechanisms by which cAMP increases STAR transcription remain uncertain [46, 47]. 
Two of the best-characterized factors regulating STAR transcription include 
Steroidogenic factor 1 (SF-1) [48, 49], and CCAAT/enhancer-binding protein β 
(C/EBPβ) [47, 50], which can cooperate with SF-1 to regulate transcription of the STAR 
promoter [51]. CREB/CREM/ATF, AP-1, and more recently, retinoic acid receptors 
(RARs) and retinoid X receptors (RXRs) [52] also regulate the STAR promoter. How 
SPON1 might interact with these factors that regulate the STAR promoter remains to be 
determined. One possible mechanism is that SPON1 interaction with receptors on the 
granulosa cell triggers a signal transduction pathway in which one or several kinases is 
activated or de-activated. Because SF-1 and  C/EBPβ are active only when 
phosphorylated, it is possible that SPON1 reduces  activity that phosphorylates these 
transcription factors, resulting in reduced SF-1 and C/EBPβ activity, and thus reduced 
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transcription of STAR. Many possible mechanisms can be postulated, and further 
experiments are necessary to dissect the mechanism linking SPON1 to reduced STAR 
promoter activity. 
2.4.4 Other mechanisms by which SPON1 may reduce STAR 
protein levels in KGN cells 
Because SPON1 had only a modest effect on reducing STAR promoter activity 
(17%), SPON1 may have mechanisms to regulate progesterone levels other than 
regulating STAR promoter activity. Here we suggest two such possibilities: a) SPON1 
may stabilize STAR protein levels, and b) SPON1 may regulate cAMP levels or activity. 
There is evidence that STAR protein levels are regulated by post-translational events 
[46]. STAR undergoes proteolytic processing in the mitochondria, although what effect 
this has on steroidogenesis remains to be understood [46]. STAR is also post-
translationally modified by several kinases, and phosphorylation of STAR on Ser194 is 
essential for maximal activity [53-55]. Secondly, because in our experiments cAMP is 
added directly to the medium, and SPON1 inhibits the effect of this cAMP, it is likely 
that SPON1 does not inhibit cAMP production, but rather a step downstream of cAMP 
production. For example, SPON1 may increase the expression of phosphodiesterases 
(PDEs), which degrade cAMP, resulting in reduced levels of cAMP, and a reduction in 
STAR and progesterone levels. 
2.4.5 Mechanisms by which SPON1 regulates cellular function in 
other model systems 
A limited number of studies in a wide variety of model systems have explored the 
mechanisms and signal transduction pathways by which SPON1 regulates cellular 
function, but no common mechanism of SPON1 action has be identified. Some studies 
suggest that SPON1 begins the signal transduction process by interacting with integrins. 
In C. elegans, SPON1 binds to muscle -integrin and is localized to integrin-containing 
sites [10]. In a human umbilical vein endothelial cell (HUVEC) model, SPON1 inhibits 
migration by blocking integrin v3 [2, 17]. Interestingly, kinases are well-known to 
associate with integrins to propagate intracellular signals [2]. Results suggesting SPON1 
may regulate kinase activity include: inhibiting phosphorylation of focal adhesion kinase 
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(FAK) and VEGF-stimulated protein kinase B (AKT) [17], and increasing 
phosphorylation of p38 MAPK  in murine neuroblastoma cells [12]. In chick ciliary 
ganglion, SPON1 increases the phosphorylation of the intracellular adaptor protein, 
disabled-1 (Dab1) and phosphorylation of AKT [13]. SPON1 also interacts with LRP8 
(low-density lipoprotein receptor-related protein 8) and APP (amyloid precursor protein) 
[56-58] but the functional significance of this is not yet known [16]. Thus, a variety of 
biological factors, signalling molecules, kinases, and proteins have been implicated in the 
mechanism of action of SPON1 in very diverse model systems. Understanding SPON1’s 
mechanism of action remains a field rich for discovery in many tissues, including the 
ovary. 
2.4.6 SPON1, PRAS40 and regulation of cell viability and/or 
proliferation 
In our study, we observed that SPON1 modestly but significantly increased both 
KGN (human) and KK-1 (mouse) cell line viability and significantly increased 
proliferation in KGN cells. Our findings suggest a role for PRAS40 in granulosa cell 
viability and proliferation. PRAS40 is a member of mTORC1 (mammalian target of 
rapamycin complex 1), which regulates cell growth, proliferation, viability, protein 
synthesis and motility [59, 60]. Significantly, mTORC1 controls ovarian follicle growth 
by regulating proliferation of granulosa cells [28] and mTORC1 has been implicated in 
ovarian cancer cell proliferation [34, 61]. mTORC1 is composed of the kinase and 
catalytic subunit, mTOR, regulatory-associated protein of mTOR (Raptor/RPTOR), 
mammalian lethal with SEC13 protein 8 (MLST8), PRAS40 (which inhibits mTORC1 
activity), and DEP domain containing MTOR-interacting protein (DEPTOR).  
mTORC1 promotes cell survival and tumourigenesis and is positively correlated 
with proliferative disease progression [61]. Within the mTORC1 complex, 
unphosphorylated PRAS40 binds Raptor and mTOR under adverse conditions, such as 
low nutrients, and inhibits activity of mTORC1 by blocking AKT1 signalling to mTOR 
and directly inhibiting binding of substrates such as the translational repressor, eukaryotic 
translation initiation factor 4E binding protein 1 (4EBP1) [62, 63]. Phosphorylation of 
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PRAS40 by AKT1 and mTOR physically removes PRAS40 from mTOR and activates 
the mTORC1 complex [63].  
A linear signalling pathway linking cell surface to function has not yet been 
established for SPON1. However, a signal transduction pathway has been established for 
the SPON1-like protein RELN. [64-67] RELN is expressed in the adult mouse ovary [65] 
and in the chicken follicle where it promotes granulosa cell proliferation [67]. The RELN 
pathway provides us with a potential mechanism of action for SPON1 because SPON1 
and RELN bind the same cell surface receptors, VLDLR and LRP8 [64, 68, 69]. RELN 
binding to VLDLR and LRP8 leads to DAB1 phosphorylation [70] which induces 
activation of AKT1, resulting in activation of mTORC1 [71]. Interestingly, SPON1 
phosphorylates both DAB1 and AKT1 in chicken ciliary ganglion [13]. Thus, there are 
many parallels between the established RELN pathway, and the emerging details of 
SPON1 signalling. Further experiments are required to investigate this intriguing 
potential pathway of SPON1 signalling. 
2.4.7 Limitation of Methods 
One of the limitations of this study is the lack of a loss-of-function approach to establish 
a requirement of SPON1 for the functions we have demonstrated. This was not due to an 
oversight or lack of effort. For over two years, we attempted to reduce SPON1 levels 
using various siRNA approaches. We tried a number of different protocols, including 
multiple primer sets from different suppliers, a number of different cell lines, culturing 
conditions, and transfection reagents. The most success we had with this approach was a 
50% reduction of SPON1 protein that lasted only 24 hours before SPON1 levels were 
restored to pre-knockdown levels. Thus, we were unable to use this loss-of-function 
approach to further support the results and conclusions of this study. Another limitation 
worth noting is that although granulosa cell lines are very useful for initial studies of 
function, they are not as physiologically relevant as rodent models, for example, and in 
vivo studies are required to complement our current data. 
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2.4.8 Conclusion 
In summary, we have made several novel discoveries in the present study. We 
identify potential functions for SPON1 in the ovary, namely, regulation of: a) granulosa 
cell steroidogenesis, b) STAR and CYP11A1 expression, c) STAR promoter activity, and 
d) granulosa cell viability and proliferation. We also identify PRAS40 as a kinase target 
that is phosphorylated in the presence of SPON1, and is potentially involved in the 
signalling pathways regulating these functions. In addition, we demonstrate that cAMP-
induced STAR protein levels are reduced by an ECM protein, and very few ECM 
proteins with this ability have been identified. These results strongly suggest that in 
addition to its role in other tissues, SPON1 plays a role in ovarian folliculogenesis by 
regulating granulosa cell function. We believe that these findings may help explain why 
SPON1 is highly overexpressed in ovarian cancer, and provide further support for its 
utility as an ovarian cancer marker.  
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3 Chapter 3: Characterization of Spondin 1 function in 
mouse ovarian folliculogenesis 
3.1 Introduction 
Folliculogenesis, followed by successful ovulation, is a complex process that 
transforms a primordial follicle, an oocyte surrounded by a single layer of pre-granulosa 
cells, into a fully-mature pre-ovulatory follicle, consisting of an oocyte surrounded by 
several layers of cumulus granulosa cells, multiple layers of mural granulosa cells, a 
fluid-filled antrum, and a layer of vascularized theca cells separated from the rest of the 
follicle by a basal lamina. In response to luteinizing hormone, ovulation occurs and the 
oocyte is released, resulting in formation of a highly-vascularized corpus luteum (CL). 
The CL produces progesterone to prepare the uterus for implantation and maintain 
pregnancy, should it occur. This process requires the action of a large number of factors, 
including pituitary hormones, steroid hormones produced by the ovary itself, the 
extracellular matrix (ECM), glycoproteins, and growth factors. Despite extensive 
characterization of many of these factors, many more remain to be discovered, as 
indicated by the numerous genome-wide expression analyses that have been carried out 
using follicles at various stages of folliculogenesis. Identification of new regulatory 
factors may point to new directions of therapeutic intervention for women since 
unexplained sub-infertility or infertility contributes to a large proportion of female 
infertility, and defects in ovulation account for the greatest proportion of causes of 
infertility. 
Spondin 1 (SPON1) was first characterized as a secreted (ECM) protein highly 
expressed in the mouse embryonic floorplate [1]. SPON1 has been primarily studied for 
its role in the central nervous system, where it regulates migration of neurons during 
early development and cell adhesion in many cell types of the central nervous system [2-
6]. In C. elegans SPON1 maintains cell-ECM adhesion in several tissues, both neural and 
non-neural [7]. SPON1 also increases cell viability in neural cells. Chicken ciliary 
ganglion cells treated with recombinant SPON1 in culture have increased viability [8]. In 
a mouse neuroblastoma cell line knockdown of SPON1 resulted in decreased survival 
under adverse conditions that was rescued by SPON1 treatment [9].  
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Several lines of evidence suggest that SPON1 regulates angiogenesis, and in fact, 
may inhibit it. Angiogenesis is the growth of new blood vessels from pre-existing vessels 
and consists of several steps. Existing blood vessels are destabilized by separation of 
endothelial cells from mural cells, including pericytes and vascular smooth muscle cells 
(vSMC). The ECM must be degraded by proteases to allow migration of endothelial and 
mural cells. These cells then migrate towards the angiogenic stimuli. And finally, 
depending on the size of the vessel, mural pericytes (small and large vessels) and vSMC 
(large vessels) reattach to promote structural integrity.  With the exception of tissue 
injury or tumour progression, angiogenesis only occurs in a few adult tissues, including 
the CL, the endometrium of the uterus, and the placenta. In relation to angiogenesis, 
SPON1 inhibits migration and tube formation by human umbilical vein endothelial 
(HUVEC) cells, and neovascularization in rat cornea [10]. SPON1 also promotes vSMC 
proliferation [11], and was isolated from bovine ovarian follicular fluid in a search for a 
factor that promoted vSMC proliferation in the ovary [11].  
Despite the fact that SPON1 mRNA is highly expressed in the ovary in humans, 
as shown by Northern blot [11] there have been few reports describing SPON1 gene 
expression in the mammalian ovary or uterus [12]. As mentioned, SPON1 was identified 
in bovine follicular fluid [11]. In addition, when ovariectomized mice are treated with 
17β-estradiol, Spon1 mRNA expression increases in both the uterus [13] and mammary 
gland [14], suggesting SPON1 may play a role in these reproductive tissues. 
Interestingly, SPON1 is also highly overexpressed in ovarian cancer [15, 16].  Our 
previous microarray studies [17] comparing the gene expression profiles of granulosa 
cells isolated from gonadotropin-treated immature (PND 23-29) C57Bl/6 wildtype (WT) 
and estrogen receptor  (ER)-null mice identified SPON1 (Spon1) expression to be 
lower in ER-null granulosa cells than in WT cells (Gene Expression Omnibus accession 
number GSE11585). Together this information points to a potentially significant role for 
SPON1 in the ovary. Given that there is evidence for a role for SPON1 in cell signalling 
in survival, differentiation and angiogenesis in other tissues, we also hypothesized that 
SPON1 may play a role in these functions in the uterus and ovary. Currently, it is not 
known in what cells of the ovary or uterus SPON1 is expressed. It is also not known 
 81 
 
whether SPON1 expression is regulated by gonadotropins, or what functional roles it 
plays in these tissues. 
Therefore, to further characterize the localization, potential function, and 
regulation of SPON1 by gonadotropins in the mouse, we examined SPON1 expression, 
localization, and regulation by follicle stimulating hormone and luteinizing hormone in 
the mouse ovary and uterus and SPON1 function in survival and steroiodogenesis in 
mouse primary granulosa cells. We also examined the potential co-localization of SPON1 
with markers of endothelial cells, pericytes, and vascular smooth muscle cells. 
Interestingly, our data point to a novel role for SPON1 in regulating cell survival and 
steroidogenesis in the ovary and angiogenesis in both the ovary and uterus.  
3.2 Materials and Methods 
3.2.1 Mice and treatments 
Experiments were performed in compliance with the guidelines set by the 
Canadian Council for Animal Care, and the policies and procedures approved by the 
University of Western Ontario Council on Animal Care (Protocol Number: 2007-042). 
All mice used were of the strain C57Bl/6. All females were weaned at PND 21, and for 
mRNA analysis or immunofluorescence were treated at PND 22-23 with saline vehicle, 
5.0 IU eCG (Sigma Chemical Co.) or 5.0 IU eCG followed 48 h later with 5.0 IU hCG 
(Sigma) unless stated otherwise. Both gonadotropins were dissolved in phosphate-
buffered saline solution and injected subcutaneously in a total volume of 0.1 ml. At 
necropsy, animals were killed by CO2-asphyxiation; and the ovaries and uterus were 
dissected, trimmed of surrounding tissue, and frozen and stored as described below. 
3.2.2 Granulosa cell isolation and culture  
To isolate granulosa cells ovaries were removed from females and immediately 
placed in a 60-mm cell culture dish on ice containing M199 medium (316-010; Wisent) 
supplemented with 1mg/ml of bovine serum albumin (BSA) (ALB003; Bioshop) 2.5 
μg/ml of amphotericin B (15240-062; Life Technologies), and 50 μg/ml of gentamicin 
(450-135-XL; Wisent). Ovaries were pooled by genotype and the GCs were then isolated 
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by manual puncture with 25-gauge needles followed by manual squeezing with a sterile 
spatula. Follicular debris was removed by filtration through a150-nm Nitex nylon 
membrane (Sefar America, Inc.) mounted in a 25-ml syringe. The GCs were pelleted by 
centrifugation at 250 x g for 5min at 4°C, washed in DMEM/F12 medium containing 1% 
penicillin/streptomycin solution (15070-063; Invitrogen) and re-centrifuged. The final 
cell pellet was re-suspended in DMEM/F12 with 1% pen/strep and counted using Trypan 
Blue and a haemocytometer. Cells were cultured in DMEM/F12 with 1% pen/strep for 
viability assays, progesterone assays, and qPCR of treated cells. 
3.2.3 RNA isolation and quantitative RT-PCR  
Ovaries and uteri were removed from virgin adult or treated prepubertal mice (see 
3.2.1) and frozen. Uteri were pulverized using a mortar and pestle on dry ice with liquid 
nitrogen prior to RNA isolation. Whole ovaries and pulverized uteri were homogenized 
in Trizol (Invitrogen) and RNA was isolated according to the manufacturer's protocol. 
RNA was further treated with DNaseI, then reverse-transcribed using Superscript II 
(Invitrogen). Complementary DNA (cDNA) levels were detected using quantitative RT-
PCR with the Viia7 Sequence Detection System (Applied Biosystems) and SYBR Green 
I dye. Primers were generated using Applied Biosystems Primer Express Software 
version 2.0. The Rpl7 primers were: forward 5’-AGCTGGCCTTTGTCATCAGAA-3’, 
reverse 5’-GACGAAGGAGCTGCAGAACCT-3’. The Spon1 primers were: forward 
primer - 5’-TTGACTGTGAACTCAGCGAGTGGT-3’, reverse primer -  
5’TCCGGGTTCGAATCATGTGACCTT-3’.  Fold changes in gene expression were 
determined by quantitation of cDNA from treated samples relative to saline samples. 
Experiments were done in triplicate. Relative gene expression was analyzed with Rpl7 as 
the control gene using the ΔΔ-CT method. Differences in gene expression between 
treatments were measured using a two-tailed, unpaired Student’s t-test. 
3.2.4 Western blot analysis 
To determine SPON1 protein levels in mouse ovaries, and granulosa cells, tissues 
were homogenized in ice-cold radioimmunoprecipitation (RIPA) buffer (150 mM sodium 
chloride, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 
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50 mM Tris, pH 8.0) and lysate concentrations measured using the DC protein assay 
(product nos. 500-0113, 500-0114, 500-0115; Bio-Rad Laboratories (Canada) Ltd.). 
Proteins were separated by SDS-PAGE and transferred to a polyvinylidene difluoride 
(PVDF) membrane. Membranes were incubated with a rabbit polyclonal anti-SPON1 
antibody (2 g/ml) (product no. ab40797; Abcam) for one hour at room temperature (rt). 
After incubation with an anti-rabbit horseradish peroxidase (HRP)-conjugated secondary 
antibody (1:10,000) (product no. 934; GE Healthcare) for one hour at rt, SPON1 levels 
were visualized with Pierce ECL Plus Western Blotting Substrate (product no. 32132; 
Fisher Scientific) on Hyperfilm (product no. CA95017-653L, VWR).  
3.2.5 Immunofluorescence 
Primary antibodies used were: Anti-SPON1 (Santa Cruz Cat. No. sc-49004), 
Anti-PECAM1/CD31 (Abcam Cat. No. ab28364), Anti-Desmin (Abcam Cat. No. 
ab15200), anti-α Smooth muscle actin (Abcam Cat. No. ab5694). Secondary antibodies 
used were: FITC-conjugated rabbit anti-goat (Sigma Cat. No. F7367), and TRITC-
conjugated donkey anti-rabbit (Abcam Cat. No. ab6799); and for confocal microscopy: 
Alexa Fluor 488 donkey anti-rabbit and Alexa Fluor 568 donkey anti-goat (Invitrogen, 
Cat. Nos. A21206, A11057). The Anti-SPON1 antibody detects a region in the C-
terminus of the protein. Dissected ovaries were embedded in Cryomatrix (Fisher 
Scientific Inc.) and frozen using liquid nitrogen. Uteri horns and whole ovaries were 
embedded in Cryomatrix and frozen using liquid nitrogen. Tissues were cut into 6 μm 
sections (in the case of the uterus, cross-sections), mounted onto slides (Fisher) and 
stored at -80°C until use. Sections were fixed with 4% formaldehyde for 10 minutes, 
rinsed three times with phosphate-buffered saline (PBS), then permeabilized with 0.1% 
Triton X-100 for 15 minutes. Sections were again rinsed three times with PBS and then 
blocked for 30 minutes with blocking solution (5% BSA in 0.1% Triton X-100). The 
tissue was then incubated overnight with primary antibody diluted in blocking solution. 
For co-localized sections slides were incubated in primary antibodies simultaneously. 
Sections were then rinsed three times in blocking solution and incubated in secondary 
antibody. For co-localized sections slides were first incubated in the TRITC-conjugated 
donkey anti-rabbit secondary then rinsed three times with blocking solution and 
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incubated in FITC-conjugated rabbit anti-goat secondary. The slides were then washed 
twice in PBS and mounted with Vectashield with 4′,6-diamidino-2-phenylindole (DAPI) 
(Vector Laboratories) diluted 1:1 with Vectashield (Vector Laboratories). Slides were 
visualized within 24 hours with an Olympus Provis AX70 upright microscope. Images 
were captured using Image-Pro 6.2 Software. Confocal analysis was performed using an 
Olympus Fluoview 1000 laser-scanning confocal microscope (Olympus).  
3.2.6 Viability Assay 
Primary granulosa cells were seeded at 40,000 cells per well in 96-well plates, 
incubated for one hour, then treated with recombinant human SPON1 (5 μg/ml; R&D 
Systems). Cell viability was measured after 24 and 48 hours using the Cell Titer 
AQueous Non-Radioactive Cell Proliferation Assay (MTS) (product no. PRG3582; 
Promega). Differences in viability between vehicle treatment alone or treatment with 
SPON1 at each time-point were analyzed by a two-tailed, unpaired, Student’s t-test. 
(PRISM 6; GraphPad). 
3.2.7 Progesterone Assay 
Primary granulosa cells were plated at 500,000 cells per well in a 24-well plate in 
DMEM/F12 supplemented with 1% Penicillin/Streptomycin (Wisent). After 24 hours, 
cells were treated with bovine serum albumin (BSA) control (250 μg/mL; BioShop 
Canada Inc.), recombinant human SPON1 (SPON1) (5 g/mL; R&D Systems, 
Minneapolis, MN), dibutyryl-cAMP (dbcAMP) (1 mM) (Enzo Life Sciences), both 
SPON1 and dbcAMP, FSH (recombinant human FSH from National Hormone and 
Peptide Program) and testosterone (National Hormone and Peptide Program), or FSH, 
testosterone, and SPON1. Media was removed after 48 hours and frozen at -80C until 
further analysis. Protein lysates were prepared using RIPA buffer supplemented with a 
protease inhibitor cocktail (1:1,000 dilution, product no. P8340-5ml; Sigma). Protein 
lysate concentrations were determined using the DC protein assay (Bio-Rad). Cell culture 
media was sent to the University of Virginia Centre for Research in Reproduction Ligand 
Assay and Analysis Core and the progesterone concentration determined by Progesterone 
radioimmunoassay (RIA). Progesterone concentrations were calculated by normalizing 
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ng/μl progesterone/well to the total protein/well. Differences in progesterone levels 
between all treatments were analyzed by one-way analysis of variance (ANOVA) 
followed by a Tukey Multiple Comparison post-hoc test (Tukey test) (PRISM6.0; 
GraphPad). 
3.3 Results 
3.3.1 Expression of Spon1 mRNA and protein in the mouse 
female reproductive organs 
Our first goal was to determine if SPON1 was expressed in the mouse ovary and 
uterus and if it was regulated by gonadotropins there. To determine if Spon1 mRNA 
levels in the ovary and uterus were regulated by the gonadotropins, mice were treated 
with equine chorionic gonadotropin (eCG), which activates the follicle stimulating 
hormone (FSH) receptor, and human chorionic gonadotropin (hCG), which stimulates the 
luteinizing hormone (LH) receptor, and induces ovulation. Prepubertal mice (PND 21-23) 
were treated with saline vehicle (48h), eCG (5 IU, 48h), or eCG followed by hCG (5 IU, 
24h). These treatments mimic the FSH-stimulated stage of folliculogenesis and the LH-
stimulated ovulation stage of folliculogenesis. Ovaries and uteri were isolated, and 
analyzed for Spon1 mRNA levels by quantitative RT-PCR analysis. In ovaries, eCG 
treatment stimulated a six-fold increase in Spon1 mRNA levels over saline-treated 
ovaries, and was reduced to 2-fold after hCG treatment (Fig. 3-1 A). In the uterus, eCG 
treatment stimulated a five-fold increase in Spon1 mRNA levels over saline-treated uteri, 
and was also reduced to 2-fold after hCG treatment (Fig. 3-1 B). Western blots performed 
with extracts of both the ovary and granulosa cells showed high levels of SPON1 (Fig. 3-
1 C, D).   
3.3.2 SPON1 localization in the adult mouse ovary and uterus 
The location of SPON1 within the ovary and uterus, to our knowledge, has never 
been identified (other than in bovine follicular fluid [11]). Therefore, we determined 
SPON1 localization using immunofluorescence in the ovaries and uterus of adult female 
mice (Fig. 3-2 A, B). In the adult mouse ovary, SPON1 localized to the theca cells (Fig. 
3-2 A, open arrow) and the interstitium between small to large follicles (Fig. 3-2 A) with  
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Figure 3-1. Expression of SPON1 mRNA in mouse ovary and uterus and protein in 
ovary and granulosa cells. 
A and B. Post-natal day (PND) 21-23 C57Bl/6 mice were treated with saline, equine 
chorionic gonadotropin (eCG) (5.0 IU per mouse) for 48 hours, or eCG (5.0 IU) for 48 
hours followed by human chorionic gonadotropin (hCG; 5.0 IU per mouse) for 24 hours. 
Ovaries and uteri from three mice were used to isolate mRNA and prepare cDNA for 
analysis by quantitative RT-PCR compared to an Rpl7 control. eCG treatment increases 
Spon1 mRNA levels in the ovary and uterus and further treatment with hCG reduces this 
expression. Data are expressed as average gene expression compared with the Rpl7 
control (± SEM of three mice). Differences in average mRNA levels between treatments 
were analyzed by two-tailed, unpaired, Student’s t-test. A. In the ovary there were 
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significant differences between saline and eCG, and eCG and eCG + hCG, P < 0.001, and 
P < 0.01, respectively. B. In the uterus there was a significant difference between saline 
and eCG, P < 0.001. ** = P < 0.01. *** = P < 0.001. C. Western blot of whole ovary and 
granulosa cells with anti-SPON1 antibody showing high expression of SPON1. For both 
ovary and granulosa cell, lanes are duplicates of the same lysate. 
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Figure 3-2. SPON1 localization in the mouse ovary and uterus. 
Immunofluorescence with an anti-SPON1 antibody was used to detect SPON1 
localization and expression in the mouse ovary (A) and uterus (B) of mice treated with 
eCG followed by hCG. A. In the ovary SPON1 was localized to the theca cells (A c, open 
triangle), corpus luteum (A a-d, higher magnification in b) and weakly in granulosa cells 
(square). SPON1 is also present in the ovarian epithelium (A c, white arrow) B. In the 
uterus SPON1 was detected in the stroma of the endometrium, and weakly in the 
epithelial cells lining the lumen or endometrial glands (B a, b, white triangle). SPON1 
was weakly detectable in the inner or outer layers of the myometrium (B a, b, open 
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triangle). Interestingly, SPON1 was also found in the stratum vasculare, the layer of large 
blood vessels located between the inner and outer layers of the myometrium (B, b, open 
square). All images are 100x magnification except A, b which is 200x. 
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weak staining in the outer granulosa layer of various follicular sizes (Fig. 3-2 A, square in 
panel a). SPON1 staining was also strikingly high within corpora lutea (Fig. 3-2 A panel 
b), and also in the ovarian epithelium (Fig. 3-2A panel a, white arrow). 
In the uterus, SPON1 was localized to the stroma of the endometrium, and weakly 
in the epithelial cells lining the lumen or endometrial glands (Fig. 3-2 B, panels a and b, 
white arrow). It was also weakly detectable in the inner and outer layers of the 
myometrium (Fig. 3-2 B, panels a and b, open arrow). Interestingly, SPON1 was 
expressed in the stratum vasculare, the layer of blood vessels located between the inner 
and outer layers of the smooth muscle of the myometrium (Fig. 3-2 B, open square). 
3.3.3 SPON1 localizes with endothelial cell markers in the mouse 
ovary 
Due to the localization of SPON1 to what appeared to be the vasculature of the 
follicle and corpus luteum of the ovary, and its expression in the uterine stratum 
vasculare and the highly-vascularized stroma, we hypothesized that SPON1 may localize 
with the vasculature in both tissues, and perhaps play a role in regulating angiogenesis in 
these tissues. To test this hypothesis, we investigated the potential co-localization of 
SPON1 with three traditional markers of vasculature, namely: a) platelet endothelial cell 
adhesion molecule 1 (PECAM1, also called CD31), a glycoprotein used as a general 
endothelial cell surface marker including pericytes b) desmin (DES), an intermediate 
filament protein that is a marker of pericytes, and c) alpha smooth muscle actin (αSMA), 
officially known as “actin, alpha 2, smooth muscle” (ACTA2), a microfilament present in 
high amounts in vascular SMC. ACTA2 is found in larger blood vessels walls, but not in 
smaller capillaries which do not contain smooth muscle. Co-localization of SPON1 with 
all markers was also examined by plotting the intensity of green (SPON1) vs. red 
(marker) pixels on an XY graph for the merged images (Appendix C).   
In the mouse ovary, PECAM1 has been shown to localize to the blood vessels in 
the theca cell compartment that surrounds the basal lamina and in the vasculature of the 
CLs [18]. As shown in Figure 3-3, we observed similar localization of PECAM1.  
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Figure 3-3. Co-localization of SPON1 and PECAM1 in the mouse ovary. 
 
 92 
 
Immunofluorescence with an anti-SPON1 and anti-PECAM1 antibody was used to detect 
SPON1 and PECAM1 localization and expression in the mouse ovary. A. Both SPON1 
(green) and PECAM1 (red) localized to the theca cell layer (white arrow) in two large 
pre-antral/preovulatory follicles. A is 100x magnification. B. A mature corpus luteum 
(CL) beside a secondary follicle. Both SPON1 (green) and PECAM1 (red) localized to 
the theca cell layer of the secondary follicle, and throughout the CL. Overlap between 
SPON1 and PECAM1 at these sites was observed (an open arrow indicates one example 
of overlap). C. A developing CL. PECAM1 (red) shows overlap with SPON1 (green) 
(white arrows indicate examples of overlap). B and C are 200x magnification. D. 
Confocal microscopy of the thecal cell layer and a developing CL (bottom) show overlap 
of SPON1 (red) and PECAM1 (green) in these areas. Mouse treatments were as follows: 
(A) eCG, 48h; (B, C, and D) eCG, 48h, followed by hCG for 24 hours. 
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Co-localization experiments using both antibodies showed a significant overlap of 
PECAM1 and SPON1 in the theca cell layer (see Fig. 3-3 A, white arrows), and in 
mature (Fig. 3-3 B, open arrow) and developing corpora lutea (Fig. 3-3 C, open arrow). 
This overlap is even more striking under the high magnification of a confocal microscope 
(Fig. 3-3 D). 
Similarly, DES localized to the theca cell layer of developing follicles (Fig. 3-4 A, 
open arrows) and the corpora lutea, but not granulosa cells. DES, like PECAM1 showed 
overlap with the SPON1 signal in the theca cells (Fig. 3-4 A, open arrows) and in the 
corpus luteum (Fig. 3-4 A, white arrows). However, co-localization of DES with SPON1 
was less dramatic than with PECAM1(Appendix C). Also, while SPON1 showed some 
expression surrounding granulosa cells, DES did not (Fig. 3-4 A, open square). 
Finally, ACTA2 was also expressed in the theca cell layer surrounding follicles (Fig. 3-4 
B), but not in the corpus luteum where large vessels are rarely present. Again, we 
observed co-localization between the SPON1 and ACTA2 signal in the theca cell layer, 
although, like DES, it was less dramatic than with PECAM1 (Appendix C). 
3.3.4 SPON1 localizes with endothelial cell markers in the mouse 
uterus 
In the uterus, we observed a high degree of co-localization between PECAM1 and 
SPON1 (Fig. 3-5, white arrows, Appendix C). An exception was that faint SPON1 
expression was observed in the luminal and glandular epithelial cells while PECAM1 was 
not (Fig. 3-5).  
Between DES and SPON1 there was only co-localization in the stroma (Fig. 3-6 A, 
Appendix C). Interestingly, DES was highly expressed in inner and outer layers of the 
myometrium and not the stratum vasculare (Fig. 3-6 A, white arrow), while SPON1 is 
expressed in the only in the stratum vasculare of the myometrium.  
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Figure 3-4. Co-localization of SPON1 with DES and ACTA2 in the mouse ovary. 
Immunofluorescence with an anti-SPON1 antibody and antibodies against 
vascular/pericyte markers, DES and ACTA2, were used to characterize the overlap 
between SPON1 and the ovarian vasculature. Panels A, a-c and B, a-c are 100x 
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magnification, A, d-f, and B, d-f are 200x. A. DES (red) localized to the blood vessels in 
the theca cell layer around a large antral follicle, and in the vasculature of the corpora 
lutea (CL), and showed a significant overlap (A, c and f) with SPON1 (green) in the theca 
cell layer (open arrow) and CL (white arrows), but not in granulosa cells, where only 
SPON1 was expressed (open square). B. ACTA2. ACTA2 localized solely to the theca 
cell layer surrounding follicles, but unlike DES, was not detected in CLs. Mouse 
treatments for all images were eCG, 48h, followed by hCG for 24 hours.  
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Figure 3-5. Co-localization of SPON1 and PECAM1 in the mouse uterus. 
Immunofluorescence with an anti-SPON1 antibody and anti-PECAM antibody was used 
to characterize the potential for overlap between SPON1 and the uterine vasculature. 
Panels a-c are 100x magnification and d-f are 200x. PECAM1 was robustly detected 
throughout the uterus, but not in the luminal and ductal epithelium. As shown in Figure 
3-2 B, SPON1 was detected in the stroma of the endometrium, and weakly in the 
epithelial cells lining the lumen or endometrial glands. Co-localization of PECAM1 with 
SPON1 appeared almost total, except for the weak luminal and ductal epithelial staining 
by SPON1 where PECAM1 was undetectable. An example of overlap in the stroma is 
shown with white arrows. Mouse treatment for all images was eCG, 48h, followed by 
hCG for 24 hours. 
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Figure 3-6. Co-localization of SPON1 with DES and ACTA2 in the mouse uterus. 
Immunofluorescence with an anti-SPON1 antibody and antibodies against 
vascular/pericyte markers, DES and ACTA2, were used to characterize the overlap 
between SPON1 and the uterine vasculature A. Desmin (DES) staining was found 
throughout the stroma but not in the luminal and ductal epithelium. Co-localization with  
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SPON1 (panel c) occurred in the stroma. B. ACTA2, as expected, was expressed 
primarily in the myometrium. Little overlap was observed between SPON1 and ACTA2. 
Mouse treatment for all images was eCG for 48h, followed by hCG for 24 hours. For 
both A and B magnification for all panels a-c was 100x and for d-f 200x. 
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Finally, ACTA2 was, unsurprisingly, expressed in both the inner and outer layers of the 
myometrium, and there was almost no co-localization between ACTA2 and SPON1 (Fig. 
3-6 B, Appendix C). 
3.3.5 SPON1 treatment increases viability of mouse granulosa 
cells  
A function of ECM proteins in the ovary is to regulate cell survival and SPON1 has been 
shown to affect survival of neural cell types. Therefore we measured the viability of 
mouse primary granulosa cells in the absence or presence of recombinant SPON1. To 
measure the effect of SPON1 on cell survival, isolated wildtype granulosa cells isolated 
from prepubertal mice were treated with recombinant SPON1 and viability was measured 
using an MTS assay. SPON1-treated cells were significantly more viable than control-
treated cells after both 24h and 48h (Fig.3-7). 
3.3.6 SPON1 treatment increases dbcAMP- and FSH-induced 
progesterone production 
SPON1 affects differentiation of nerve cells, a function known to be carried out 
by ECM proteins in ovarian cell types during folliculogenesis. An indicator of 
differentiation in granulosa cells is the ability to produce 17β-estradiol and progesterone 
but the effects of SPON1 on steroid production have never been measured in any cell 
type. Therefore we quantified 17β-estradiol and progesterone production of mouse 
primary granulosa cells by measuring both steroids in culture medium following various 
treatments. SPON1 treatment increased progesterone production in cells co-treated with 
either dibutyryl-cAMP (dbcAMP) or FSH and testosterone but had no effect on 
progesterone production by itself  (Fig. 3-8). However, SPON1 treatment had no effect 
on 17β-estradiol production (data not shown). 
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Figure 3-7. SPON1 treatment increases viability of mouse primary granulosa cells. 
Measurement of cell viability by an MTS assay at 24 and 48 hours following treatment 
with control BSA (bovine serum albumin) or recombinant SPON1. Each bar represents 
the mean ± SD of triplicate measurements within one representative experiment. Three 
experiments were performed and all were significant. Differences in viability between 
vehicle treatment alone or treatment with SPON1 at each time-point were analyzed by a 
two-tailed, unpaired Student’s t-test, P < 0.05. There were significant differences between 
treatment at both 24h and 48h, P <0.05. * = P <0.05. 
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Figure 3-8. SPON1 treatment increases progesterone output of mouse primary 
granulosa cells. 
Measurement of progesterone levels by radioimmunoassay normalized to protein levels.  
Each bar represents mean ± SEM of triplicate experiments. Differences in progesterone 
level were measured by one-way ANOVA followed by a Tukey Multiple Comparison 
post-hoc test (Tukey test).  There was a statistical significance between treatments as 
determined by one-way ANOVA, F (6, 14) = 39.01, P = >0.0001. There were no 
statistical differences between BSA (SPON1 control), water (dbcAMP and FSH + T 
control), and SPON1 treatment. A significant difference was found between water and 
dbcAMP, P <0.05, between dbcAMP and dbcAMP + SPON1, P <0.05, between water 
and FSH + T, P <0.01, and between FSH + T and FSH + T + SPON1, P <0.001. * = P 
<0.05, ** = P <0.01, and *** = P <0.001 
 
0
2
4
6
8
10
P
4
/
g
 p
r
o
te
in
BSA
Spondin 1
Water
dbcAMP
dbcAMP + Spondin 1
FSH + T
FSH + T + Spondin 1
*
*
**
***
 102 
 
3.4 Discussion 
3.4.1 Summary of findings 
In this study, we have shown that SPON1 protein is highly expressed in the ovary 
and uterus. We show that eCG increases the mRNA levels of Spon1 in both mouse ovary 
and uterus, and that hCG following this treatment reduces Spon1 levels almost to pre-
treatment levels. In the ovary, we show that SPON1 strongly localizes to the theca cell 
layer and the corpus luteum, as well as weakly in the granulosa cell layer. In the uterus, 
SPON1 is strongly present in the stroma of the endometrium, but only weakly in the 
epithelial cells of the lumen or glands. SPON1 is very minimally expressed in the inner 
and outer layers of the myometrium, but is expressed in the stratum vasculare between 
these layers. Interestingly, in both ovary and uterus, SPON1 co-localizes with the 
vascular markers, PECAM1 and DES, but not a marker of larger vessels containing 
smooth muscle actin (ACTA2). These results suggest that SPON1 may play a role in 
regulating angiogenesis in the ovary and uterus, particularly in developing capillaries. We 
show that SPON1-treated granulosa cells have increased viability and that both dbcAMP- 
and FSH with testosterone-induced production of progesterone is elevated with SPON1 
co-treatment. Taken together these results strongly suggest an important role for SPON1 
in folliculogenesis and pregnancy.  
3.4.2 Regulation of SPON1 expression by gonadotropins 
Given our discovery of a potential role for SPON1 in female reproductive 
angiogenesis and granulosa cell function, it is not surprising that Spon1 mRNA levels are 
regulated by gonadotropins. Dynamic angiogenesis occurs throughout the menstrual or 
estrus cycle in both ovary and uterus, while FSH induced cell growth and differentiation 
of granulosa cells is required for folliculogenesis. In the ovary, cAMP signalling may 
increase Spon1 transcription, as is common for many eCG-regulated genes. It is 
particularly interesting that after hCG treatment (mimicking the LH surge), Spon1 levels 
are reduced, suggesting that Spon1, like many other genes, is downregulated following 
the LH surge that transitions the follicle from growth to ovulation to luteinization. In the 
uterus, it is also possible that circulating estrogens (resulting from eCG treatment) 
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increase Spon1 levels, rather than cAMP-mediated events, given that Spon1 mRNA 
levels are increased by estradiol in the mouse uterus [13].  
Many questions remain to be answered to understand the exact role of SPON1 in 
the ovary and uterus. First, further studies using in situ hybridization are needed to 
determine which cells within the ovary produce SPON1. Our data (unpublished) indicate 
that isolated granulosa cells produce both Spon1 mRNA and protein. The presence of 
SPON1 in the theca cell layer suggests either that theca cells express SPON1 or that 
granulosa cells secrete SPON1 to theca cells across the basal lamina.  
3.4.3 SPON1 localizes with PECAM1 and DES, but not ACTA2 in 
the mouse ovary and uterus 
In the mouse ovary, PECAM1, a marker of both endothelial cells and pericytes, 
localizes to the blood vessels in the theca cell layer and in the vasculature of the corpora 
lutea [18]. We observed similar localization of SPON1 in the ovary by co-localization 
experiments. In the uterus, PECAM1 has been shown to localize to the highly-
vascularized stromal endometrium [19], and we observe almost identical colocalization 
of SPON1. Co-localization with PECAM1 suggests that SPON1 plays a role in both 
corpus luteum angiogenesis and in the vascularization of the theca cell layer as follicles 
grow and progress through folliculogenesis.  
DES is a marker of pericytes or smooth muscle cells [20] in a tissue-dependent 
manner.  DES localization has previously been characterized in the ovaries of various 
avian and mammalian species, including the emu, ostrich, rat, and African Giant Rat [21-
25]. The localization of DES we observed in the mouse ovary is consistent with that 
published for the rat [25]. In the rat, DES was “dispersed in the CL”, and in the “arteries 
around the CL, as well as elsewhere in the ovary” [25], including the theca cell layer. 
Thus, the partial co-localization we observed between DES and SPON1 in the ovary 
would be consistent with its previously published location within the ovary. In the adult 
mouse, “the developing endometrial stroma … strongly expressed DES”, as did the 
myometrial layers [26]. As we also observed, there was no DES staining in the 
endometrial epithelium, where we observed only weak SPON1 staining. Thus, the DES 
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localization we observe in the uterus is consistent with what has previously been 
published, and suggests SPON1 may play a role in uterine angiogenesis due to its 
proximity to this marker. 
The localization of ACTA2, which is a marker of the internal structure of smooth 
muscle cells and pericytes in blood vessel walls, has also been studied in various species. 
In the mouse ACTA2 has previously been shown to be present in the theca cell layer 
surrounding follicles but not expressed in the CL [27]. In contrast, in the African Giant 
Rat ACTA2 is still strongly present in the theca cell layer, but is also seen within limited 
pockets within the CLs [24]. Consistent with the previous work, in our study, we found 
ACTA2 in the theca and interstitium but not the CLs. The lack of presence of ACTA2 
suggests that only capillaries, which do not contain smooth muscle, are present in the 
mouse CL.  In the uterus of mouse and rat, DES and ACTA2 localization has also been 
characterized. In the uterus, by far the predominant location of ACTA2 is reported to be 
in the myometrial layers [26, 28, 29], and this is consistent with our studies, as we saw 
expression of ACTA2 solely in the myometrium. 
3.4.4 A role for SPON1 in ovarian and uterine angiogenesis? 
These localization studies suggest that SPON1 associates most closely with 
capillaries and smaller vessels where we observed high co-localization with PECAM1. 
The lesser co-localization of SPON1 with ACTA2 in the theca cell matrix suggests 
SPON1 may also associate with larger blood vessels although not as closely. Ovulation 
results in angiogenesis from pre-existing vessels of the theca cell layer into the newly 
formed corpora lutea, producing an abundant vasculature that touches almost every cell 
in the corpus luteum. We have observed the presence of SPON1 early in this process and 
once the vasculature has formed suggesting that SPON1 is involved in the entire process. 
Angiogenesis also takes place in the developing follicle before ovulation, in the 
interstitial and theca cell layers. We have observed SPON1 in both ovarian sites of 
angiogenesis. 
The lack of ACTA2 in the mouse CL suggests that there are no smooth muscle 
cells and only capillaries are present. Therefore, although DES is a marker of smooth 
 105 
 
muscle cells and pericytes, in the CL in our study, it is most likely only showing the 
presence of pericytes. Thus, when SPON1 and DES are co-localized in the CL, we feel 
this is supportive of SPON1’s role in angiogenesis, as pericytes are critical for the 
process of angiogenesis. 
We therefore postulate that SPON1 regulates angiogenesis in the ovary and 
uterus. While SPON1 may either promote or inhibit angiogenesis, there is more evidence 
in the literature to support an inhibitory role for angiogenesis in the ovary, especially 
since SPON1 mediated vSMC growth could be interpreted as pro- or anti-angiogenic, as 
vSMCs surrounding mature vessels is a last step in angiogenesis. Treatment of HUVECS 
with recombinant human SPON1 inhibits the spreading of HUVECs plated onto anti-αvβ3 
integrin antibodies, and also inhibits VEGF-mediated HUVEC tube formation [10]. 
Intriguingly, endostatin, a naturally-occurring 20 kDa angiogenesis inhibitor found in 
humans, also inhibits angiogenesis by binding to integrin αvβ3  [30]. Therefore, we 
speculate that in both ovary and uterus, SPON1 may participate in regulating the size or 
length of blood vessels, possibly limiting the size of vessels in the corpus luteum to only 
capillaries. This provides a possible explanation of SPON1 overexpression in ovarian 
cancer, ie. SPON1 may be attempting to inhibit angiogenesis, but failing.  
3.4.5 SPON1 affects cell survival and differentiation of primary 
granulosa cells  
SPON1 has been shown to affect cell survival and cell differentiation in neural 
and non-neural cells. We show that treatment of wildtype mouse granulosa cells with 
recombinant SPON1 led to increased viability. We could not determine if there was 
increased proliferation as primary granulosa cells that are not treated with hormones or 
cultured with fetal bovine serum do not proliferate. As mentioned above, SPON1 
promotes cell viability of chicken ciliary ganglion[8] and mouse neuroblastoma cells [9]. 
In chicken ciliary ganglion this was achieved through increased active TGFβ levels [8] 
while in neuroblastoma cells loss of viability following SPON1 knockdown was 
attributed to lower IL-6 levels [9]. With current knowledge a likely candidate for the 
effect of SPON1 on cell viability in granulosa cells is alteration of TGFβ signalling, as 
TGFβ is an important protein in folliculogenesis and also regulates IL-6.  
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Differentiation of early granulosa and theca cells to steroid producing cells is an 
essential step in folliculogenesis. Differentiation of cells due to SPON1 has been 
observed in nerve cells [5], cementoblasts [31], and chondrocytes [32]. The ability of 
SPON1 to alter gene expression has been seen in chondrocytes where expression of 
proteins involved in ECM remodelling is increased by SPON1 [32, 33]. Again, these 
changes in gene expression were brought about by increased levels of TGFβ [32, 33]. 
Granulosa cells treated with SPON1 and either dbcAMP or FSH and testosterone resulted 
in increased production of progesterone compared to cells that were not treated with 
SPON1.  Because SPON1 affects both viability and steroid production of wildtype 
granulosa cells we hypothesize that it may play an important role in vivo in these 
functions.   
3.4.6 Conclusion 
In summary, we have shown for the first time that SPON1 is expressed in both the 
ovary and uterus and that expression changes in response to gonadotropins. We have also 
shown that SPON1 localizes to the theca cell layer and corpus luteum in the mouse ovary, 
and to the endometrial stroma and the myometrial stratum vasculare of the mouse uterus. 
Through co-localization studies with vascular cell markers we have shown that SPON1 is 
present at small and, to a lesser extent, large blood vessels. This is the first in vivo 
evidence showing that SPON1 is associated with blood vessels and therefore may have a  
role in angiogenesis. We have also found possible functional roles for SPON1 within 
ovarian folliculogenesis as a mediator of FSH-induced granulosa cell proliferation and 
differentiation. These studies suggest the enticing possibility that SPON1 may be a new 
regulator of angiogenesis and folliculogenesis with potential therapeutic implications. 
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4 Chapter 4 – Spondin 1 is required for normal ovarian 
function in Mus musculus 
This chapter is based on a manuscript that has been prepared but not yet submitted. 
4.1 Introduction 
The ovary functions to prepare oocytes for ovulation and fertilization via 
folliculogenesis and as an endocrine gland producing steroid hormones to act on itself 
and other organs. These processes require involvement of the extracellular matrix (ECM). 
The ovary is constantly undergoing tissue remodelling as follicles grow and follicular 
cells differentiate, and the ECM modulates these changes [1]. ECM proteins affect 
follicle growth and development [2] and are involved in granulosa cell proliferation, 
survival, morphology and steroidogenesis [3-6]. Numerous studies have found that 
granulosa cells or ovarian tissue cultured with ECM proteins, such as laminin, 
fibronectin, and collagen IV, or Matrigel (a gelatinous protein mixture rich in ECM 
proteins) are more viable than those grown with other growth media [2, 3, 7].  
As folliculogenesis progresses, the composition of the ECM changes and several 
different types of ECM proteins are required for normal ovarian cell differentiation and 
proliferation. These include the above mentioned laminins, fibronectins, and collagens, as 
well as proteoglycans with heparan sulfate or chondroitin sulfate side chains. 
Proteoglycans are involved in several cellular processes including cell adhesion, ligand-
receptor signalling, and basement membrane organization [8]. Matrix metalloproteinases 
(MMPs) degrade ECM proteins to remodel the ECM [1, 5]. In addition to supporting 
cells physically, ECM proteins are also important for signal transduction [9]. Integrins are 
often responsible for signal transduction in cell-ECM interactions. There are several 
examples of impaired fertility in knockout mouse models where ECM genes are 
disrupted, including MMP9 [10], integrin-β1 [11], Tnfaip6 [12] and ADAMTS-1[13-15]. 
However, because the ECM is important for normal function in all tissues, mutations or 
deletions of specific ECM proteins are often lethal and effects on fertility cannot be 
evaluated, or the deletion results in no phenotypic changes due to functional redundancy. 
 112 
 
Spondin 1 (SPON1) is a secreted ECM glycoprotein encoded by the gene Spon1 
[16]. It was initially studied for its role in neuron outgrowth during embryonic 
development [17-22]; however, Spon1 is also expressed in other tissues such as ovary, 
kidney, bone, and small intestine, where several other functions for SPON1 have been 
uncovered. In C. elegans Spondin 1 interacts with integrins to maintain cell adhesion 
[23]. In bone, chondrocyte differentiation and endochondral bone formation are regulated 
by SPON1 in mice [24] and expression of SPON1 is high in human osteoarthritic 
cartilage [25]. In chondrocytes and cartilage, treatment with SPON1 increased levels of 
MMP-13 [24, 25] and in cartilage, SPON1 increased the active levels of TGFβ [25].  
There is compelling evidence that SPON1 plays a role in the ovary. Spon1 
expression increases in response to 17β-estradiol in the mouse mammary gland [26] and 
the uterus [27]. SPON1 isolated from bovine ovarian follicular fluid increases 
proliferation of rat vascular smooth muscle cells activity, and inhibits tube formation of 
human umbilical vein endothelial cells, suggesting a role in angiogenesis [28, 29]. 
SPON1 has also been identified as an ovarian cancer marker [30-32].  
 The SPON1 protein is comprised of: a) an N-terminal reeler domain, homologous 
to a domain in the protein, Reelin, b) a spondin domain homologous to domains in 
Spondin 2 (Mindin/M-spondin), and c) six thrombospondin type 1 repeats (TSRs). 
Several members of the thrombospondin superfamily are known to be involved in normal 
ovarian function. Thrombospondin -1 and -2 are both expressed in the ovary and regulate 
angiogenesis [33, 34]. R-spondin is expressed in the developing ovary and female 
knockout mice have masculinized gonads and impaired ovulation [35-37]. A disintegrin 
and metalloproteinase with thrombospondin repeats 1 (ADAMTS-1) knockout mice have 
defective follicular growth, abnormal steroid gene mRNA expression, and are subfertile 
[13, 15]. 
The SPON1 knockout mouse (Spon1
-/-
) is viable and so far has been studied for 
its potential role in osteoarthritis [38] but its fertility has not been rigorously examined. 
Spon1
-/- 
mice have increased bone mass compared to controls, possibly brought about due 
to reduced levels of TGFβ-1 resulting in increased Smad1/5 phosphorylation. In the 
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present study we sought to elucidate the role of SPON1 in female fertility and the ovary 
using Spon1-null (Spon1
-/-
) mouse as a model.  
4.2 Materials and Methods 
4.2.1 Mice and Treatments 
Experiments were performed in compliance with the guidelines set by the 
Canadian Council for Animal Care and the policies and procedures approved by The 
University of Western Ontario Council on Animal Care. Investigations were conducted in 
accordance with the National Research Council’s Guide for Care and Use of Laboratory 
Animals. Wildtype C57Bl6 (Spon1
+/+
) and Spon1
-/-
 mice were kindly provided by Dr. 
Steven Abramson (New York University). Genotyping was performed as in Palmer et al. 
2014 [38]. Mice were bred heterozygous x heterozygous and litter mates were used for all 
experiments, with the exception of counting COCs. For superovulation experiments 
involving gonadotropin treatment, postnatal day 23-28 Spon1
+/+
 and Spon1
-/-
 female mice 
were treated with saline or 5.0 IU equine chorionic gonadotropin (eCG) (Sigma) for 48 
hours followed by 5.0 IU human chorionic gonadotropin (hCG) (Sigma) for the indicated 
times.  
4.2.2 Granulosa Cell Isolation and Cell Culture 
To isolate granulosa cells (GCs), ovaries were removed from Spon1
+/+
 or Spon1
-/-
 
females and immediately placed in a 60-mm cell culture dish on ice containing M199 
medium (product no. 316-010; Wisent) supplemented with 1 mg/ml of bovine serum 
albumin (BSA) (product no. ALB003; BioShop), 2.5 μg/ml of amphotericin B (product 
no. 15240-062; Life Technologies), and 50 μg/ml of gentamicin (product no. 450-135-
XL; Wisent). Ovaries were pooled by genotype and manually punctured with 25-gauge 
needles followed by pressure applied with a sterile spatula. Follicular debris was removed 
by filtration through a150-nm Nitex nylon membrane (Sefar America, Inc.) mounted in a 
25-ml syringe. GCs were pelleted by centrifugation at 250 x g for 5 min at 4°C, washed 
in DMEM/F12 medium containing 1% penicillin/streptomycin solution (pen/strep) 
(product no. 15070-063; Invitrogen) and centrifuged as previously described. The final 
cell pellet was re-suspended in DMEM/F12 containing 1% pen/strep and the cells 
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counted using Trypan Blue and a haemocytometer. Cells were cultured in DMEM/F12 
with 1% penicillin/streptomycin for viability assays, progesterone assays, and 
quantitative RT-PCR (qPCR). 
4.2.3 Quantitative RT-PCR  
To measure mRNA levels of Spon1 in Spon1
+/+
 mice ovaries, uterus, and isolated 
granulosa cells, RNA was isolated using Trizol (product no. 15596; Life Technologies). 
RNA was reverse transcribed using Superscript II reverse transcriptase (product no. 
18064-014; Life Technologies). Rpl7, a ribosomal protein, was used as a control. Relative 
gene expression levels were measured using SYBR Green Master Mix and Rpl7 (forward 
primer – 5’-AGCTGGCCTTTGTCATCAGAA-3’, reverse primer –5’-
GACGAAGGAGCTGCAGAACCT-3’) and Spon1 (forward primer - 5’-
TTGACTGTGAACTCAGCGAGTGGT-3’, reverse primer -  
5’TCCGGGTTCGAATCATGTGACCTT-3’) cDNA levels were determined in 384-well 
plates with 10 μl reactions using the Applied Biosystems 7900HT Fast Real Time PCR 
System. Relative gene expression was analyzed with Rpl7 as the control gene using the 
ΔΔ-CT method. To measure mRNA levels of other genes in ovaries of Spon1+/+ and 
Spon1
-/-
 mice, RNA was isolated using the Qiagen RNeasy mini kit, the second step of 
which requires the Qiashredder kit (product nos. 74104 and 79654, respectively; Qiagen). 
Relative mRNA levels were determined using TaqMan Fast Advanced Master Mix 
(product no. 4444963; Life Technologies) and TaqMan Gene Expression Assays (product 
no. 4331182; Life Technologies) probe/primer sets. cDNA levels were determined as 
described for Spon1.For all qPCR experiments, differences in expression between 
genotypes or treatments were measured using a two-tailed, unpaired Student’s t-test with 
Welch’s correction or a two-way ANOVA with Fisher’s LSD post-hoc test (PRISM6; 
GraphPad). 
4.2.4 Western Blot 
To determine SPON1 protein levels in mouse ovaries, and granulosa cells, tissues 
were homogenized in ice-cold Radioimmunoprecipitation (RIPA) buffer (150 mM 
sodium chloride, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl 
sulphate, 50 mM Tris, pH 8.0) and lysate concentrations measured using the DC protein 
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assay (product nos. 500-0113, 500-0114, 500-0115; Bio-Rad Laboratories (Canada) 
Ltd.). Proteins were separated by SDS-PAGE and transferred to a polyvinylidene 
difluoride (PVDF) membrane. Membranes were incubated with a rabbit polyclonal anti-
SPON1 antibody (2 g/ml) (product no. ab40797; Abcam) for one hour at room 
temperature (rt). After incubation with an anti-rabbit horseradish peroxidase (HRP)-
conjugated secondary antibody (1:10,000) (product no. 934; GE Healthcare) for one hour 
at rt, SPON1 levels were visualized with Pierce ECL Plus Western Blotting Substrate 
(product no. 32132; Fisher Scientific) on Hyperfilm (product no. CA95017-653L, VWR).  
4.2.5 Immunofluorescence 
Spon1
+/+
 and Spon1
-/-
 mice were treated with saline or 5.0 IU equine chorionic 
gonadotropin (eCG) (Sigma) for 48 hours followed by 5.0 IU human chorionic 
gonadotropin (hCG) (Sigma) for 24 hours.  Ovaries were removed and immediately 
frozen in Cryomatrix (product no. 67-690-06, Fisher Scientific). Ovaries were sectioned 
at 5 μm and placed on glass slides (product no. 12-550, Fisher Scientific), then stored at -
80°C until further use. Prior to exposure to antibody, slides were allowed to adjust to rt. 
Ovaries were fixed in 4% formaldehyde (product no. FOR201, BioShop) and rinsed three 
times for 5 minutes with PBS. Sections were permeabilized with 0.1% Triton X-100 
(product no. X100, Sigma) in PBS and rinsed three times with PBS. Sections were 
blocked with 5% BSA and 0.1% Triton X-100 in PBS. Slides were incubated in primary 
antibody (goat anti-SPON1, product no. sc-49004, Santa Cruz Biotechnology, detects a 
region in the C-terminus of Spondin 1) in blocking solution for one hour at rt, rinsed with 
blocking solution, and then incubated in secondary antibody (FITC-conjugated rabbit 
anti-goat, product no. F7357, Sigma) in blocking solution for one hour at rt. Slides were 
rinsed twice for five minutes in PBS and then dried and mounted with Vectashield 
Mounting Medium with DAPI (product no. H-1200, Vector Laboratories) 1:1 with 
Vectashield (product no. H-1000, Vector Laboratories). Slides were stored at 4°C and 
visualized with an Olympus Provis AX70 upright microscope. Images were captured 
using Image-Pro 6.2 Software. 
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4.2.6 Progesterone Assay 
Serum isolated from treated mice was sent to the University of Virginia Centre for 
Research in Reproduction Ligand Assay and Analysis Core (Charlottesville, VA) and the 
progesterone concentration determined by Progesterone radioimmunoassay (RIA). 
Differences in progesterone levels between all treatments were analyzed by one-way 
analysis of variance (ANOVA) followed by a Tukey Multiple Comparison post-hoc test 
(Tukey test) (PRISM6.0; GraphPad). 
4.2.7 Histology 
Ovaries were removed from Spon1
+/+ 
and Spon1
-/-
 mice and fixed in 4% 
formaldehyde (BioShop) for 48 hours and transferred to 70% ethanol. Ovaries were then 
processed (through ethanol rinses), embedded, sectioned at 5 μm, and stained with  
hematoxylin and eosin (Molecular Pathology Core Facility, Robarts Research Institute, 
London, ON, Canada). Slides were scanned using the Aperio CS2 and visualised using 
Aperio Imagescope software (Leica Biosystems). 
4.2.8 Continuous Breeding Study 
To determine if Spon1
-/-
 female mice were as fertile as Spon1
+/+
 females, 8-week 
old female Spon1
+/+
 and Spon1
-/-
 mice were bred for six months with Spon1
+/+
 male mice 
who were proven breeders. Nine pairs for each genotype were individually housed, and 
cages were checked for pups every morning. Differences between genotypes in litter size 
and days between litters were analyzed using a two-tailed, unpaired Student’s t-test 
(PRISM6; GraphPad). 
4.2.9 Assessment of ovulation capacity 
To determine if Spon1
-/- 
mice have a diminished ovulation capacity, six-week old 
Spon1
+/+
 and Spon1
-/-
mice were treated with eCG (5 IU) for 48 hours followed by hCG (5 
IU) for 14 hours. Oviducts were removed and placed in M2 medium with hyaluronidase 
warmed to 37°C. Oviducts were punctured to release cumulus-oocyte complexes (COCs), 
and the complexes allowed to dissociate to facilitate counting of oocytes. Differences 
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between genotypes in number of oocytes were analyzed using a two-tailed, unpaired 
Student’s t-test (PRISM6; GraphPad). 
4.2.10 Ovarian Weight Analysis 
To determine if Spon1
-/-
 ovaries differed in weight from Spon1
+/+ 
ovaries, 4-week, 
8-week, and 12-week old mice were euthanized and then weighed to obtain body weight. 
Ovaries were then removed and weighed. Ovarian weight was normalized to body 
weight, and the differences between genotypes analyzed using a two-tailed, unpaired 
Student’s t-test (PRISM6; GraphPad). 
4.3 Results 
4.3.1 SPON1 expression and localization in the Spon1+/+ mouse 
ovary 
To determine if SPON1 is expressed in the whole ovary and in granulosa cells, 
Western blots and qPCR were performed. SPON1 was expressed at both the gene and 
protein levels in granulosa cells and whole ovary (Fig. 4-1 A). Spon1 mRNA levels were 
also altered following treatment with eCG or eCG + hCG (Fig. 4-1 B). eCG increased 
Spon1 mRNA levels, while hCG reduced this increase when administered after eCG. 
Immunofluorescence showed that in the ovaries of pre-pubertal, untreated Spon1
+/+
 mice, 
SPON1 was localized in mural granulosa cells and more strongly in thecal cells (Fig. 4-1 
C). In ovaries treated with eCG for 48 hours followed by hCG for 24 hours (to induce 
ovulation) SPON1 was additionally localized within corpora lutea (Fig. 4-1 D).  
4.3.2 Spon1-/- female mice are subfertile 
Spon1
-/- 
mice are viable but no long-term study has determined if they are as 
fertile as Spon1
+/+
 mice. To determine breeding capacity, a long-term breeding study 
comparing Spon1
-/-
 and Spon1
+/+
 mice was conducted. Eight-week old females were 
housed with proven Spon1
+/+
 males for six months. Spon1
-/-
 females  produce 
significantly less pups per litter (7.9 ± 0.32, n=9) than their Spon1
+/+
 counterparts (10.1 ± 
0.46, n=8) (Fig. 4-2 A). However there was no significant difference in the number of  
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Figure 4-1. SPON1 is expressed in mouse granulosa cells, ovary, and uterus. 
A. mRNA expression of Spon1 in ovary isolated from immature mice that were 
untreated, or treated with 48h eCG, or 48h eCG followed by 24h hCG (also in Fig. 3-1). 
Differences in gene expression between treatments were measured using a two-tailed, 
unpaired Student’s t-test, P < 0.05. There was a significant difference between control 
and eCG treatment, P < 0.001, and a significant difference between eCG and eCG + hCG 
treatment P < 0.01, but no difference between saline and eCG + hCG. B. Western blots of  
SPON1 in granulosa cells and ovary (also in Fig. 3-1).  C. Immunofluorescence of 
SPON1 in the ovary isolated from immature mice treated for 48h with eCG. D. 
Immunofluorescence of SPON1 in the ovary isolated from immature mice treated 
following 48h eCG and 24h hCG treatment. ** = P < 0.01, *** = P <0.001. 
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Figure 4-2. Spon1
-/-
 females are subfertile and have smaller ovaries. 
Differences between genotype for A, B and C were measured using a two-tailed, 
unpaired Student’s t-test, P < 0.05. A. Mean litter size per female in a six-month breeding 
study. Each data point represents one female. Spon1
-/- 
 females (7.8 ± 0.32) has 
significantly less pups per litter than Spon1
+/+ 
females (10.1 ± 0.46), P < 0.01.  B. Mean 
days between litters per female. Each data point represents one female. There was no 
significant difference between genotypes (Spon1
+/+ 
28.5 ± 2.3, Spon1
-/-
 27.3 ± 2.1). C. 
Ovulatory capacity was measured by counting COCs (cumulus oophorus complexes) 
following 48h eCG and 14h hCG treatment. Each data point represents one female (two 
ovaries). Spon1
-/- 
females ovulated significantly less oocytes (45.6 ± 4.6) than Spon1
+/+ 
females (61.8 ± 0.48), P <0.01. D. Ovarian weight per body weight at 4, 8, and 12 weeks. 
Ovarian weight per body weight was analyzed using a two-way ANOVA followed by a 
Tukey test, P < 0.05. There was no effect of age but the effect of genotype was 
significant, F (2, 24) = 21.4 , P = 0.0001. There were no significant differences between 
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genotype at 4 weeks, but at 8 and 12 weeks Spon1
-/- 
ovaries were significantly smaller 
than Spon1
+/+ 
, P < 0.05 and P < 0.01 respectively. * = P < 0.05; ** = P < 0.01 
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days between litters (29.0 for Spon1
+/+
, 27.3 for Spon1
-/-
 ) (Fig. 4-2 B) or between litters 
per breeding female (4.8 for Spon1
+/+
, 5.4 for Spon1
-/-
). 
4.3.3 Spon1-/- female mice have diminished ovulatory capacity and 
smaller ovaries 
To determine if a lack of ovulated oocytes contributed to female Spon1
-/- 
subfertility, superovulation studies were performed. Spon1
+/+
 mice ovulated an average of 
61.8 oocytes/mouse while Spon1
-/- 
ovulated 45.6 oocytes/mouse (Fig. 4-2 C). This 
significant decrease in ovulation strongly mirrors the decrease in number of pups 
observed in the breeding study, as Spon1
-/- 
females ovulated 73% of oocytes compared to 
Spon1
+/+
 females and have litters 77% that of Spon1
+/+ 
females. Because Spon1
-/-
 mice 
have a diminished ovulatory capacity, ovarian size was measured and corrected for body 
weight (body weight was not significantly different by genotype).  
No difference in the ovary/body weight ratio was observed at four weeks; 
however at eight and twelve weeks, Spon1
-/- 
ovaries were significantly smaller than 
Spon1
+/+ 
ovaries, relative to body weight, (Spon1
-/- 
ovary/body weight is 65% that of 
Spon1
+/+ 
at both eight and twelve weeks)  (Fig. 4-2 D). 
4.3.4 Ovaries from cycling Spon1-/- mice contain abnormal corpora 
lutea  
To determine the cause of the subfertility and diminished ovulatory capacity of 
Spon1
-/-
 mice, we examined the histology of ovaries from normally cycling Spon1
+/+ 
and 
Spon1
-/- 
mice at various ages. In Spon1
-/- 
ovaries, follicles at all stages of growth were 
observed. At three weeks of age there were no differences seen between genotypes (Fig. 
4-3 A, B). However, at four months, Spon1
-/-
 ovaries, although largely normal otherwise, 
(Fig. 4-3 C, D), contained abnormal CLs with granulosa cells that failed to luteinize (Fig. 
4-3 E, F), though the thecal cells appeared to have luteinized normally. At eight and 
twelve months, no differences in ovarian histology between genotypes were observed 
(not shown). When mice were treated between 23-28 days of age with eCG for 48 hours, 
or eCG for 48 hours followed by hCG for 4, 16, 24, 72 or 120 hours, no differences in 
histology were observed between genotypes. 
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Figure 4-3. Spon1
-/-
 female mice are grossly normal with some abnormal corpora 
lutea. 
Spon1
+/+
 and Spon1
-/-
 ovaries at three weeks and four months of age. A. Three-week old 
Spon1
+/+
 ovary. B. Three-week old Spon1
-/-
 ovary. C. Four-month old Spon1
+/+
 ovary. D. 
Four-month old Spon1
-/-
 ovary. E. Four-month old Spon1
-/-
 ovary with un-luteinized CL. 
F. Close-up of un-luteinized CL in four-month old Spon1
-/-
 ovary. 
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4.3.5 Sex determination genes are dysregulated in Spon1-/- mice 
Because female Spon1
-/-
 mice are subfertile, have a diminished ovulatory 
capacity, and in a subgroup of CLs, have a granulosa cell-to-luteal cell transition defect, 
we investigated the ovarian mRNA levels of several genes important to the process of 
folliculogenesis in untreated mice (Appendix D – List of Genes). Despite subtle 
histological abnormalities in corpora lutea of cycling mice, we did not see any differences 
in gene expression between genotypes for the luteinizing hormone/choriogonadotropin 
receptor (Lhcgr), or LH-responsive genes: progesterone receptor (Pgr), prostaglandin F 
receptor (Ptgfr), prostaglandin-endoperoxide synthase 2 (Ptgs2) and 20α-hydroxysteroid 
dehydrogenase (Akr1c18) (Fig. 4-4 A, B, data not shown). No differences between 
genotypes were observed in the mRNA levels of the steroidogenesis genes, scavenger 
receptor B1 (Scarb1), steroid acute regulatory protein (StAR), cholesterol side chain 
cleavage enzyme (Cyp11a1), and aromatase (Cyp19a1) (Fig. 4-4 C, D, E, F) following 
eCG +/- hCG treatment, which is consistent with the similar serum progesterone levels 
observed under the same treatment conditions in Spon1
+/+
 and Spon1
-/-
 females (Fig. 4-5).   
Surprisingly, expression of Scarb1 and Star was higher in Spon1
-/-
 pre-pubertal 
untreated ovaries than Spon1
+/+
 (Fig. 4-6 A, B). Scarb1 and Star are involved in uptake of 
cholesterol and localization. At this stage of ovarian development, steroidogenesis is 
minimal and the lack of difference in Cyp11 expression at the same time suggests 
steroidogenesis has not been prematurely activated in Spon1
-/-
 ovaries.  However, because 
we see this dysregulation before puberty, we decided to measure expression of genes 
involved in earlier ovarian processes. Interestingly, mRNA levels of the sex 
determination and primordial follicle activation inhibitor, Amh, were higher in immature 
Spon1
-/- 
ovaries than in Spon1
+/+ 
ovaries. mRNA levels of Sox9, another sex 
determination gene, were also significantly higher in immature Spon1
-/- 
ovaries than in 
Spon1
+/+ 
ovaries  (Fig. 4-6 C, D).     
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Figure 4-4. Expression of steroidogenesis genes following gonadotropin treatment is 
unchanged in Spon1
-/-
 ovaries. 
Mice were treated with eCG for 48h or eCG for 48h followed by hCG for 4h then ovaries 
were removed and mRNA levels were determined by reverse transcription and qPCR. 
Gene expression for all genes was normalized to Rpl7. Differences of genotype in genes 
A-F were analyzed by a two-tailed, unpaired Student’s t-test with Welch’s correction, P < 
0.05. There was no difference between genotypes for genes A-F. The specific 
gonadotropin treatment was chosen for genes based on when they would initially increase 
in vivo. A and C-F were measured following 48h eCG treatment. B was measured after 
48h eCG followed by 4h hCG treatment. A. Lhcgr, luteinizing hormone receptor. B. Pgr, 
progesterone receptor. C. Cyp11a1, cholesterol side-chain cleavage enzyme. D. Cyp19a1, 
aromatase. E. Scarb1, scavenger receptor class B, member 1. F. Star, steroid acute 
regulatory protein.   
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Figure 4-5. Serum progesterone levels are unchanged following gonadotropin 
treatment of Spon1
-/-
 females. 
Mice were treated with eCG for 48h or eCG for 48h followed by hCG for 4h or 24h. 
Serum was removed and progesterone was measured by radioimmunoassay. Differences 
in progesterone levels between treatments were measured by a two-way ANOVA which 
found a significant effect of treatment but not genotype, F (2, 16) =13.92, P=0.0003. 
There were no significant differences between genotype at any treatment as measured by 
Tukey multiple comparison post-hoc test.  
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Figure 4-6. Expression of steroidogenesis and sex determination genes is altered in 
early folliculogenesis in Spon1
-/-
 ovaries. 
Ovaries were removed from prepubertal mice (23-27 days old) that were untreated or 
treated for 48h with eCG. mRNA levels were determined by reverse transcription and 
qPCR. For genes A and B differences in gene expression were analyzed by a two-tailed, 
unpaired Student’s t-test with Welch’s correction, P < 0.05. C and D were analyzed using 
a two-way ANOVA with a Fisher’s LSD post-hoc test comparing genotype means of 
each treatment. A. Gene expression of Scarb1 in prepubertal mice was significantly 
different between Spon1
+/+
 and Spon1
-/-
, P < 0.01. B. Gene expression of Star in 
prepubertal mice was significantly different between Spon1
+/+
 and Spon1
-/-
, P < 0.05. C. 
Gene expression of Amh was not affected by treatment but was significantly affected by 
genotype F (1, 19) = 13.42, P = 0.0017. Between Spon1
+/+
 and Spon1
-/- 
prepubertal mice 
expression was significantly different, P < 0.05, and between Spon1
+/+
 and Spon1
-/- 
mice 
treated for 48h with eCG expression was significantly different, P < 0.01. D. Gene 
expression of Sox9 was not affected by treatment but was significantly affected by 
genotype F (1, 19) = 12.13, P = 0.0025. Between Spon1
+/+
 and Spon1
-/- 
prepubertal mice 
expression was significantly different, P < 0.05 , and between Spon1
+/+
 and Spon1
-/- 
mice 
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treated for 48h with eCG expression was significantly different, P < 0.05. * = P < 0.05; 
** = P < 0.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 128 
 
4.4 Discussion 
There has been previous work reporting that SPON1 is found within the ovary 
and that it may play a role in ovarian cancer but no work has examined the role of 
SPON1 in fertility. We report for the first time that SPON1 plays a role in normal 
functioning of the ovary in vivo. 
4.4.1 SPON1 expression is regulated by gonadotropins 
We have shown that Spon1 expression in the ovary and uterus responds to follicle 
stimulating hormone (FSH) and luteinizing hormone (LH), which strongly suggests a role 
for SPON1 in normal ovarian function. The pattern we see of LH downregulating the 
FSH-induced expression of Spon1 is a well-established observation in ovarian biology. 
When the LH surge occurs and begins the process of ovulation, FSH-dependent 
expression of many steroidogenesis genes and granulosa cell growth-promoting factors is 
terminated. This suggests that SPON1 is involved in one or more FSH-dependent 
processes such as steroid production or cell growth.  
4.4.2 SPON1 localization suggests a role in angiogenesis 
The location of SPON1 within the follicle changes as the follicle grows and 
differentiates. This is seen following treatment of the mouse with eCG and hCG. When a 
prepubertal mouse is treated with eCG to initiate growth of follicles SPON1 is seen in the 
theca cell compartment and in the mural granulosa cells. We have shown that SPON1 is 
expressed by granulosa cells and by the whole ovary but can only speculate on its 
function in theca cells. Theca cells may produce their own SPON1 or granulosa cells may 
secrete SPON1 that could passively diffuse through the basal lamina to theca cells as a 
signalling molecule. In its function as a signalling molecule in nerve outgrowth, SPON1 
is known to be cleaved, and the resulting two polypeptides localize to different areas [17, 
18, 39]. Therefore, we may be detecting the localization of only one cleavage product of 
SPON1 (the antibody used recognizes a C-terminal region), although we did not see any 
cleavage products on Western blots in the ovary or granulosa cells.  
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Following ovulation, angiogenesis occurs rapidly within the corpus luteum to 
provide cholesterol substrate for progesterone production. After treatment with hCG to 
induce ovulation, SPON1 localizes to string or tube-like structures within the corpus 
luteum. The location of SPON1 within these structures suggests a potential role in 
angiogenesis. This is supported by the fact that other thrombospondin family members 
are known to have a role in fertility and ovarian angiogenesis [40, 41] and by its previous 
discovery as a molecule within bovine follicular fluid that affects growth of rat aortic 
vascular smooth muscle cells [28]. The dual localization of SPON1 to theca cells where 
vascularization occurs and the corpus luteum where angiogenesis occurs further 
strengthens this hypothesis. 
4.4.3 Subfertility of Spon1-/- female mice 
We found that Spon1
-/-
 female mice are subfertile as they produce litters 23% 
smaller than Spon1
+/+
 females. However, there was no difference in the average number 
of days between birth of litters. This suggests that the subfertility arises from a lack of 
fertilizable oocytes or an inability to maintain embryos/fetuses and not from an inability 
to become pregnant or an altered estrous cycle.  Indeed, when we measured ovulatory 
capacity following superovulation, Spon1
-/- 
females ovulated 27% less oocytes then 
Spon1
+/+ 
females. Interestingly, although there are only minor and incompletely penetrant 
histological differences between Spon1
+/+
 and Spon1
-/-
 ovaries, Spon1
-/- 
ovaries are 
smaller post-puberty while the mice themselves are the same size regardless of genotype.  
A decrease in ovulatory capacity could arise from defects at any stage of 
folliculogenesis; loss of primordial germ cells or improper nest breakdown, improper 
primordial follicle formation, inhibition of primordial follicle activation, inability of 
secondary follicles to respond to FSH or LH, and inability of pre-ovulatory follicles to 
respond to LH could all result in less or no oocytes ovulated. Since Spon1
-/- 
ovaries are 
smaller but contain all classes of follicle it is plausible that less primordial follicles are 
recruited and the overall pool of follicles is smaller. Examples of knockout mice with 
smaller ovaries compared to body weight are few and, most often, are the result of 
arrested folliculogenesis at some stage prior to ovulation. Fshb
-/-
 and Fshr
-/-
 ovaries do 
not contain any follicles beyond the secondary stage and Lhcgr
-/- 
ovaries contain no 
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follicles that mature beyond the early antral stage. Ovaries treated with a bone 
morphogenetic protein-4 (BMP-4) antibody are smaller than untreated ovaries due to loss 
of oocytes and follicles and increased apoptosis of all cell types [42]. Examples of mouse 
models with smaller ovaries that contain all classes of follicles are not common, but a 
subfertile mouse null for E6-associated protein (E6-AP), an estrogen receptor co-
activator,  has decreased ovarian size compared to wildtype until 10 weeks of age [43]. 
However, there are examples of mice with histologically normal ovaries with 
impaired ovulatory capacity. Bmp15
-/-
 knockout mice are subfertile due to decreased 
ovulation but are otherwise histologically normal compared to wildtype [44]. 
4.4.4 Corpus luteum abnormalities  
The histological differences in CLs consisted of granulosa cells that failed to 
luteinize although theca cells did. This feature suggests a Spon1-dependent difference 
between theca cells and granulosa cells within the same follicle and possible altered gene 
expression of steroidogenesis genes. However, subsequent mRNA expression analysis of 
genes involved in the process of luteinization, Lhcgr, Pgr, Ptgfr, Ptgs2, and Akr1c18, 
revealed no differences between Spon1
+/+
 and Spon1
-/-
 ovaries. This lack of differences 
could be explained by variation between CLs or incomplete penetrance of the failure to 
luteinize phenotype, as normal CLs that are present could mask any gene expression 
differences within the abnormal structures. It is also unlikely that these abnormal CLs are 
affecting fertility as normal CLs could compensate for lack of progesterone and therefore 
minor malfunctions in luteinization would not affect fertilization or pregnancy. 
4.4.5 Increased expression of Amh and Sox9 in the immature 
mouse ovary 
AMH, anti-mullerian hormone, and SOX9, SRY-box 9, are both sex determining 
proteins involved in the development of the testes. SOX9 regulates the transcription of 
AMH, while AMH suppresses the formation of the mullerian duct and therefore the 
development of the female reproductive system. Therefore the elevated mRNA levels of 
Amh that we see in Spon1
-/-
 mice prior to and following FSH treatment may result from 
the overexpression of Sox9 following the same treatment. Genotypically XY mice null 
 131 
 
for Sox9 undergo male to female sex reversal [45] and XX mice over-expressing Sox9 
undergo female to male sex reversal [46]. Genotypically XX transgenic mice 
overexpressing Amh develop no uterus, have a blind vagina, and although ovaries are 
present at birth, they lose germ cells and develop seminiferous tubule-like structures after 
two weeks and by adulthood are lost completely [47]. Female mice lacking Amh were 
initially thought to be phenotypically normal [48], however, it was found that these mice 
experience over-activation of primordial follicles [49]. In contrast, primordial follicle 
activation is inhibited in wildtype ovaries treated with AMH [50]. This suggests a model 
where the increased expression of Amh we see in Spon1
-/-
 ovaries could be responsible 
for the decrease in ovulated oocytes and the smaller number of CLs at eight weeks in 
untreated females either by lack of activation of primordial follicles or decreased 
sensitivity to FSH of pre-antral follicles.  These changes could also explain the decrease 
in ovarian size seen in Spon1
-/- 
females and of note is the fact that Amh
-/-
 ovaries weigh 
1.8x their wildtype counterparts at four months [49].   
Of note, in previous work characterizing the Spon1
-/- mouse, TGFβ1 serum levels 
were decreased and this was proposed as the reason for higher bone mass [38]. AMH is a 
TGFβ family member and therefore, the increased expression of AMH we observe is the 
second example of dysregulation of a TGFβ family member in the Spon1-/- mouse. SOX9 
is directly regulated by TGFβ and, although most often upregulated [51, 52], has been 
shown to be downregulated by TGFβ as well [53]. Therefore, a model where lower 
TGFβ1 levels increase Sox9 expression and subsequently Amh expression is possible. 
4.4.6 Conclusion 
We have reported for the first time a role for SPON1 in mammalian fertility. The 
Spon1
-/- 
female mouse is subfertile, and has less ovulatory capacity and smaller ovaries 
post-puberty than Spon1
+/+
 females. Because the phenotype is subtle, future experiments 
measuring the expression of proteins homologous to SPON1 could be performed to 
discover compensatory mechanisms. We found that loss of Spon1 results in early 
dysregulation of Amh and Sox9 expression which may be causing decreased ovulatory 
capacity. This is the second instance of Spon1
-/- 
mice demonstrating dysregulation of a 
TGFβ family member protein, and therefore future work should be undertaken to 
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determine how SPON1 might be involved in TGFβ superfamily signalling in this model.  
This work is a first step towards defining the role of SPON1 within the healthy ovary. 
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5  Chapter 5 - Discussion 
5.1 Summary: A Role for Spondin 1 in the Ovary  
 Prior to this investigation, Spondin 1 had not been extensively studied in the 
ovary. The first indication that Spondin 1 is functional within the ovary was its discovery 
in bovine follicular fluid and classification as a major vSMC growth promoting factor [1]. 
The first evidence that Spondin 1 may play a role in fertility in mice was its 
downregulation by 2.5-fold in granulosa cells (GCs) of infertile estrogen receptor β Esr2-
/- 
females versus fertile Esr2
+/- 
females [2]. This Esr2
-/-
 data along with data indicating 
that 17β-estradiol increases Spon1 mRNA levels in the mammary gland [3] and uterus [4] 
imply that Spon1 is, at least indirectly, regulated by estrogens. Spondin 1 is also a 
biomarker for ovarian cancer suggesting that it may be important in progression of the 
disease [5, 6]. Founded on this evidence, we hypothesized that Spondin 1 is important in 
ovarian folliculogenesis.  
In this work I establish that Spondin 1 does indeed play a role within the ovary 
(Fig. 5-1). This was accomplished by characterizing its expression and function in 
granulosa cell lines, wildtype mouse primary GCs and whole ovary, and Spon1
-/-
 whole 
ovaries. We were unable to prove direct regulation of Spon1
-/- 
transcription by 17β-
estradiol (Section 5.2), but uncovered the first evidence that Spon1 transcription is 
regulated by gonadotropins in the ovary and uterus, with expression increasing after eCG 
treatment (which mimics FSH) and decreasing following hCG treatment (which mimics 
LH). In Chapters 2 and 3, I show that Spondin 1 promotes viability of human (KGN) and 
mouse (KK-1) granulosa tumour cell lines, as well as mouse primary GCs. This increased 
viability may result from increased signalling of the mTORC1 complex following 
phosphorylation of PRAS40. Spondin 1 affects steroidogenesis by altering the mRNA 
levels of steroidogenic genes (Chapters 2, 3, and 4), protein levels (Chapter 3), and 
progesterone levels (Chapter 2 and 3). In Chapter 3, we provide the first in vivo evidence 
that Spondin 1 may play a role in angiogenesis by demonstrating its co-localization with 
protein markers of vascularization in the ovary and uterus. Finally, in Chapter 4, we show 
that the Spon1
-/- 
female mouse is subfertile, producing litters that are smaller than 
Spon1
+/+
, possibly due to decreases in ovulated oocytes and ovarian size. 
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Effects of 
Spondin 1 
Granulosa Cell 
Tumour Cell Line 
(KGN) 
Mouse Primary 
Granulosa cells 
and Whole Ovary 
Knockout of 
Spondin 1 in 
mouse (ovarian 
effects) 
Steroidogenesis 
↓ Progesterone 
secretion; Spondin 
1 decreased mRNA 
and protein 
expression of STAR 
↑ Progesterone 
secretion 
No effect on serum 
levels of 
progesterone; 
Spon1
-/-
 prepubertal 
ovaries had 
increased 
expression of Star, 
Scarb1 
Viability 
↑ cell viability and 
proliferation; 
Spondin 1 
increased 
phosphorylation of 
PRAS40, an 
inhibitor of 
mTORC1 
↑ cell viability 
Not measured; no 
histological 
indication of 
decreased growth 
Angiogenesis N/A 
Spondin 1 co-
localized with 
PECAM1/CD31 
and DESMIN 
(endothelial and 
vascular mural cell 
markers) in the 
ovary 
No histological 
indication of 
abnormal 
angiogenesis; no 
differences in 
mRNA expression 
of VEGF or 
PECAM 
Fertility N/A N/A 
Subfertile as 
measured by litter 
size; decreased 
ovulation; 
decreased ovarian 
weight; 
luteinization 
defects; Spon1
-/-
 
prepubertal ovaries 
had increased 
expression of Sox9, 
and Amh 
Figure 5-1. Summary of Results. 
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5.2 Gonadotropin Responsiveness of Spon1 in the 
Female Reproductive System 
In this investigation we present evidence that Spon1 mRNA expression is 
upregulated by FSH and downregulated by LH in both the mouse ovary and uterus. This 
expression pattern mimics that of many other genes in the ovary that are involved in 
FSH-induced follicle growth and steroidogenesis. These genes are either not essential or 
function in a different role when FSH-regulated processes are halted following the LH 
surge. A classic example of this is Cyp19a1, which encodes aromatase, the enzyme 
responsible for 17β-estradiol production, whose expression decreases dramatically after 
the LH surge. Prior to this investigation, examples of Spon1 gene regulation within the 
mouse female reproductive system included possible estrogen regulation in the uterus, 
mammary gland, and ovary. In both the uterus and mammary gland, expression of Spon1 
following 17β-estradiol treatment was increased roughly ten-fold [3, 4]. In the ovaries of 
Esr2
-/-
 mice expression of Spon1 was 2.5-fold lower than those of heterozygous mice [7]. 
This led to the hypothesis that Spon1 may be directly regulated by estrogens and 
subsequent experiments to identify an estrogen-responsive region in the Spon1 promoter 
were performed.  
Within the mouse promoter we identified four identical non-conserved, non-
canonical estrogen response elements (EREs) upstream of the transcriptional start site 
(TSS). The canonical ERE sequence is 5’-GGTCAnnTGACC-3’ and the four sequences 
within the Spon1 mouse promoter, found approximately 2 kb from the TSS, are 5’-
GGTTAGATGATG-3’. Within the same region two half-EREs 5’-GGTCA-3’ are 
conserved in Gorilla gorilla, Homo sapiens, and Pan troglodytes. We cloned this region 
into a luciferase construct to conduct promoter-reporter assays, but found no evidence of 
estrogen responsiveness. As this experiment was performed in vitro and with a partial 
promoter it cannot conclusively be stated that there is no direct effect of estrogen on 
Spon1. This result is not unexpected given that often EREs are not found within the 
proximal promoter of genes, but are well-known to be located great distances from the 
genes they regulate [8]. However, because transcription of a gene by FSH is most often 
propagated by signalling through cAMP, and estrogen is also known to increase levels of 
 142 
 
cAMP [9], it is probable that Spon1 is a cAMP responsive gene. This theory is 
strengthened by the presence in the Spon1 promoter of two half-cAMP response elements 
(CREs), 5’-CGTCA-3’, one 2kb upstream of the TSS and one in the 5’ untranslated 
region. These sequences are conserved in Gorilla gorilla, Homo sapiens, and Pan 
troglodytes. Of note is the fact that LH also accomplishes signalling through cAMP [10], 
so although Spon1 is likely cAMP-responsive, additional factors must control its 
differential regulation by FSH and LH. 
5.3 Functional Roles of Spondin 1 in the Ovary 
5.3.1 Viability 
 Prior to this investigation, a role for Spondin 1 in increasing cellular viability was 
seen in chicken ciliary ganglion [11] and a neuroblastoma cell line [12]. We have now 
shown that Spondin 1 increases viability of primary mouse GCs (Chapter 3), as well as 
human and mouse granulosa tumour cell lines (Chapter 2). The increase in viability of 
Spondin 1-treated GCs coincides with increased Spon1 mRNA expression following 
eCG/FSH treatment. Chicken ciliary ganglion studies implicated both TGFβ activity and 
APP signalling through DAB-1 in increasing viability, while blocking both the 
reeler/spondin domains and the TSR domains inhibited Spondin 1’s effects [11]. In 
neuroblastoma cells, viability was attributed to changes in levels of IL-6 [12], which, as 
discussed in Chapter 3, can be regulated by TGFβ. TGFβ is a promoter of granulosa cell 
proliferation [13, 14] and is likely a factor in Spondin 1-induced viability.  
Here we provide the first evidence that the mTORC1 complex, via its activation 
following PRAS40 phosphorylation, may be involved in Spondin 1-induced increases in 
viability of GCs. As discussed in Chapter 2, Reelin promotes granulosa cell viability in 
chicken ovaries by binding LRP8 or VLDLR, which phosphorylate DAB-1 and activate 
the AKT pathway [15]. Reelin has also been shown to activate mTOR via increased AKT 
phosphorylation [16]. Our new evidence that Spondin 1 increases phosphorylation of 
PRAS40, coupled with past studies showing parallels between Spondin 1 and Reelin 
receptor binding, and DAB-1 and AKT phosphorylation, strongly suggests a similar 
mechanism of action for Spondin 1.  
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To date, identified functional Spondin 1 receptors include LRP8, VLDLR, and 
APP. Spondin 1 can induce clustering of these receptors with other proteins, including 
LRP8 with APP, but not LRP8 with VLDLR [17]. In the chicken ciliary ganglion APP 
but not LRP8 or VLDLR was expressed and therefore APP was identified as the Spondin 
1 receptor responsible for increased viability. Expression of Spondin 1’s receptors within 
the ovary has not been extensively studied, but during chicken folliculogenesis VLDLR 
and LRP8 are present in GCs at all stages [18] and in the cow LRP8 is present in GCs of 
dominant/preovulatory follicles [15]. Expression of these receptors in rodent models has 
been shown but their locations are unknown [19, 20].  
I propose that Spondin 1, like Reelin, activates either LRP8 or VLDLR, possibly 
both, in our granulosa cell models. These receptors activate DAB-1, which activates the 
AKT/PI3K pathway. AKT is responsible for phosphorylation of PRAS40, which removes 
inhibition of mTORC1 activity. Increased activity of mTORC1 would then increase the 
viability and possibly proliferation of GCs. This could also be achieved through the 
interaction of Spondin 1 and APP, although expression of APP in the ovary is currently 
unknown. It is also possible that increased TGFβ signalling activates the AKT/PI3K 
pathway and subsequently mTORC1 (Appendix E). 
5.3.2 Steroidogenesis  
Based on our data, interpretation of Spondin 1’s effects on steroidogenesis is 
much more complex than its role in viability. In Chapter 2, Spondin 1 decreased 
progesterone levels following dbcAMP treatment in the human granulosa tumour cell 
line, KGN, while in Chapter 3 Spondin 1 increased progesterone levels following 
dbcAMP or FSH and testosterone treatment in mouse primary GCs. The simplest 
explanation for this is that neither KGNs nor primary mouse GCs are a perfect model for 
GCs in vivo and differences between the two models are not unexpected. This is 
especially true for KGNs in terms of the steroidogenesis pathway. KGNs produce little 
17β-estradiol but respond to dbcAMP to produce progesterone [21]. Mouse primary 
granulosa cells in culture must adapt to loss of interactions with oocytes and theca cells 
and, although in vivo they primarily produce 17β-estradiol and minimal progesterone, in 
vitro they produce higher levels of progesterone. It is possible that Spondin 1 inhibits 
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expression of progesterone production genes in cells it “recognizes” as GCs while 
promoting expression of progesterone production in cells it “recognizes” as luteinized. 
This could occur due to the vastly different expression patterns of genes in granulosa 
cells under the influence of FSH compared to LH.  
 The functional interaction of Spondin 1 with LRP8 and VLDLR, as well as its 
interaction of unknown purpose with LRP2 and LRP4 [22], is intriguing, as these 
receptors are involved in cholesterol transport across the cell membrane. In the cow 
ovary, where LRP8 and VLDLR are proposed to deliver cholesterol to follicular cells, 
these receptors were expressed at different times and in different locations depending on 
follicular stage and cell type [23]. If Spondin 1 signalled through these receptors it could 
affect steroidogenesis differently depending on the specific receptor present (Appendix 
E).  
Finally, the variable action of Spondin 1 in steroidogenesis could simply be due to 
the difference in species of KGNs (human) and primary mouse GCs. Several processes in 
folliculogenesis are known to occur in a species-specific manner, for example, larger 
mammals, such as humans and cows, possess dominant follicles while rodents do not. 
The specifics of steroidogenic regulation by Spondin 1 will need to be more thoroughly 
studied in the future, but the identification of Spondin 1 as a factor in the process is 
extremely novel. 
5.3.3 Angiogenesis  
As discussed in 5.2, the upregulation of Spon1 mRNA after eCG/FSH treatment 
and downregulation following hCG/LH treatment suggests that Spondin 1 is involved in 
FSH-regulated processes such as granulosa cell proliferation and steroidogenesis, 
discussed in 5.3.1 and 5.3.2. However, expression of Spon1 is not lost completely 
following LH exposure, and the presence of Spondin 1 in the corpus luteum suggests that, 
following downregulation by LH, Spondin 1 still plays a role in the ovary. In Chapter 3, 
Spondin 1 co-localized with markers of vascularization, and PECAM1 in particular 
showed a similar pattern of localization to Spondin 1. We also co-localized Spondin 1 
with PECAM1 in the kidney and found that Spondin 1 is localized to the vasculature, 
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particularly glomerular capillaries, in this tissue, as well (Appendix F). This suggests that 
Spondin 1 may play a role in vascularization in general. The proximity of Spondin 1 to 
vasculature in theca cells and to developing capillaries within the corpus luteum, as well 
as previous in vitro studies with endothelial and vSMCs [1], lead us to hypothesize that 
Spondin 1 is involved in ovarian angiogenesis.  
 A possible signalling mechanism for Spondin 1 regulation of angiogenesis is 
blockade of integrin αvβ3, which caused inhibition of HUVEC migration [24]. In the 
ovary, integrin β3 is expressed in the theca cells and in the corpus luteum in a pattern 
similar to Spondin 1, but integrin αv is only expressed in granulosa cells of multi-layer 
follicles [25]. This suggests that, although Spondin 1 can interact with integrin αvβ3, this 
is not the case within the ovary. However, if Spondin 1 interacts directly with integrin β3, 
a different integrin α subunit coupled with β3 may be involved in Spondin 1 regulation of 
angiogenesis within the ovary (Appendix E). 
 The ovarian mechanism of anti-angiogenesis of TSP-1 may provide insight into 
the role of Spondin 1 in angiogenesis. TSP-1 inhibits endothelial cell proliferation and 
induces apoptosis [26, 27], while Spondin 1 did not inhibit proliferation of endothelial 
cells, just migration and tube formation [24]. TSP-1 directly regulates levels of vascular 
endothelial growth factor (VEGF) in the ovary by binding and internalizing it via LRP1 
[28], a receptor which has never been shown to interact with Spondin 1. TSP-1 knockout 
ovaries are significantly hypervascularized with increased levels of PECAM1 and VEGF. 
We saw no such phenotype in Spon1
-/- 
ovaries and found no mRNA expression 
differences for either gene following hCG treatment (Appendix G). The expression and 
localization of Tsp-1 in the ovary also greatly differs from Spondin 1. In rat primary 
granulosa cells Thbs1 (the gene encoding TSP-1) expression was not affected by FSH 
treatment but was increased following LH treatment [29]. In rat ovaries TSP-1 is found in 
GCs of all follicles, and all cells of the CL early in its formation, but not in its later stages 
[29]. In contrast, Spondin 1 localized to theca cells and faintly in granulosa cells and was 
present in CLs at early and later stages. Therefore the role Spondin 1 is playing in 
angiogenesis within the ovary is not likely to be similar to that of TSP-1. I propose that 
Spondin 1 is involved in limiting the growth of blood vessels, particularly capillaries, by 
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promoting their maturation, which halts growth. Spondin 1 may even be involved in 
recruiting pericytes or vSMC to stabilize new blood vessels. If Spondin 1 signals to stop 
growth and promote maturation it could explain why, in vitro, Spondin 1 inhibits 
migration and tube formation of endothelial cells and promotes proliferation of vSMC. 
The presence of Spondin 1 at capillaries in the kidney, where blood vessels are 
maintained but do not grow and regress, also supports this hypothesis.  
5.4 Influence of Spondin 1 on Female Fertility 
In the Spon1
-/-
 female, we report a diminished ovulatory capacity of 27% that 
strongly coincides with the 23% decrease in litter size and 35% decrease in ovarian 
weight. A decrease in ovulatory capacity could arise from defects at any stage of 
folliculogenesis. Loss of primordial germ cells such as in deleted in azoospermia-like, 
Dazl
-/-
 [30] and Smad5
-/-
 [31] female mice, or improper nest breakdown, seen in Ngf 
(nerve growth factor) knockouts [32], would result in complete loss of ovulation. 
Complete loss of ovulation would also occur following improper primordial follicle 
formation as seen in Foxl2
LacZ
 mice where GCs fail to differentiate from squamous to 
cuboidal, resulting in a lack of primary and secondary follicles [33]. Inhibition of 
primordial follicle activation is required to avoid premature ovarian failure but in several 
knockout mouse models, activation is accelerated or overly inhibited. AMH treatment of 
ovaries results in activation of fewer primordial follicles than controls, while loss of 
AMH results in premature activation of all primordial follicles. The same over-activation 
is seen in Pten
-/-
 females [34]. If follicles fail to respond to FSH and estrogen they will 
not grow to the antral and pre-ovulatory stages. These effects are seen in estrogen 
receptor knockout females and Fshb
-/-
 and Fshr
-/- 
mice. If pre-ovulatory follicles fail to 
fully respond to LH, ovulation will not occur. Lhcgr
-/- 
mice lack pre-ovulatory follicles 
and have no CLs. Pgr
-/- 
and Bmp15
-/- 
females both respond to LH and form CLs but often 
oocytes are not expelled and remained trapped. It is unlikely that Spon1
-/- 
females are not 
responding to FSH or LH as all follicle stages are present, from primordial to corpus 
luteum and we did not see any trapped oocytes. With our current knowledge of the 
Spon1
-/- 
ovary the most likely explanation of subfertility is that the decrease in ovulated 
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oocytes results from inhibition of activation of a subset of primordial follicles due to 
overexpression of AMH.  
A similar mechanism involving TGFβ and mTOR could also be hypothesized. 
mTOR signalling is important but not essential for primordial follicle activation and, as 
discussed in 5.3.1, TGFβ has been shown to activate mTOR signalling. In the Spon1-/- 
mouse levels of circulating active TGFβ are decreased and it is therefore possible that 
mTOR activity is also decreased. If mTOR inhibition is occurring in the Spon1
-/- 
ovary it 
could result in subfertility, especially if both AMH overexpression and mTOR inhibition 
were acting to suppress activation.  
5.5 Spondin 1 as a Matricellular Protein 
 Within the ECM, a subclass of proteins has been designated as “matricellular”. 
The definition of matricellular is continuously being updated as new research expands 
our knowledge of these proteins. In the most general terms, matricellular proteins are 
ECM proteins that are involved in cell-matrix signalling but are not required for 
structural integrity. Some thrombospondins are often classified as matricellular proteins, 
especially TSP-1 and -2, however mention of Spondin 1 as a member of this group is 
extremely rare, and in fact only one example could be found in the literature. Important 
characteristics of matricellular proteins, besides being non-structural ECM signalling 
molecules, include: a) expression in areas of development, growth, or high turnover, b) 
interactions with multiple signalling pathways via ECM structural components, cell 
surface receptors, and other ECM signalling proteins, such as growth factors, c) context-
dependent, possibly opposing, functional roles, d) a subtle or normal phenotype when 
knocked out, and e) status as a biomarker for a specific disease (reviewed in [35-38]). We 
know that Spondin 1 is expressed in areas of development (nervous system), and growth 
and turnover (ovary and bone), that Spondin 1 interacts with multiple different proteins 
including cell surface receptors (LRP8, VLDLR, APP) and growth factors (TGFβ), and 
that Spondin 1 is a biomarker for ovarian cancer. In this work I have shown that Spondin 
1 may act in a context-dependent manner to affect angiogenesis and possibly 
steroidogenesis in the ovary and that the phenotype of the Spon1
-/- 
mouse is indeed subtle. 
Observed within the context of a matricellular protein, as I believe Spondin 1 should be 
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classified, the seemingly conflicting roles of Spondin 1 in progesterone production and 
corpus luteum angiogenesis, as well as the mild subfertility of the Spon1
-/-
 female mouse, 
are to be expected.  
5.6 Future Directions 
5.6.1 Functional Redundancy of Spondin 1 
 In this work I have shown that Spondin 1 has functional roles in the ovary, 
including cell viability, proliferation, steroidogenesis, and possibly angiogenesis. In the 
literature, examples of Spondin 1 function include: nerve development and outgrowth, 
nerve cell viability and differentiation, neural and non-neural cell adhesion, proliferation 
of vascular smooth muscle cells, inhibition of endothelial cell tube formation, and 
chondrocyte and cementoblast differentiation. If Spondin 1 were indispensable within 
these roles then loss of function via knockout or mutation would be expected to result in 
infertility, severe impairment of nervous system development, vascularization, cartilage 
and bone development, and potential lethality. However, besides being mildly subfertile, 
exhibiting increased bone mass, and decreased TGFβ1 serum levels, the Spon1-/- null 
mouse has a grossly normal phenotype. None of the aforementioned functions seem to be 
impaired, suggesting that Spondin 1 is functionally redundant in most cases. This is not 
unexpected as there are several proteins, sharing domains with Spondin 1, which may be 
differentially regulated following loss of Spon1. To determine if this is the case 
expression studies of these proteins could be undertaken. Thrombospondin-1, -2, and 
Reelin have already been studied within the ovary of some species for both their 
expression and localization, while Spondin 2 has not. mRNA and protein expression of 
these candidates in untreated and gonadotropin treated Spon1
+/+
 and Spon1
-/-
 ovaries 
would determine if regulation is altered following loss of Spondin 1, while 
immunofluorescence following the same treatments would determine if these proteins 
have altered their locations within the ovary to compensate for loss of Spondin 1. If any 
of these candidate proteins were found to have significantly altered expression in the 
Spon1
-/- 
ovary, double knockouts of Spon1 and that protein could provide further insight 
into Spondin 1’s roles, both in the ovary and elsewhere. 
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5.6.2 Elucidation of Spondin 1 Signalling Mechanisms 
 The temporal expression and location of Spondin 1 receptors, LRP8, VLDLR, and 
APP, is currently unknown in the mouse ovary. Therefore the model that I propose of 
Spondin 1 signalling through these receptors remains a theory, but provides a testable 
hypothesis. Characterization of these receptors and their target, DAB-1, by expression 
and localization studies in gonadotropin treated mice could shed light on their 
involvement. Functional assays with blocking of these proteins by antibody or siRNA in 
cell lines or primary GCs could test the hypothesis. These could include viability assays 
and steroid assays using our current methods, as well as measuring phosphorylation of 
downstream targets, DAB-1, AKT, and PRAS40. Other proteins potentially involved in 
the proposed mechanisms could be studied to determine their roles in Spondin 1 
functions, including AKT, mTOR, and TGFβ. The role of TGFβ in Spondin 1 function is 
particularly interesting as TGFβ signalling is involved in regulating many cellular 
functions and a decrease in circulating active TGFβ, as seen in the Spon1-/- mouse, could 
have many implications. The interaction of Spondin 1 with integrins could also be 
examined as blockade of integrin αvβ3 by Spondin 1was implicated in inhibiting HUVEC 
migration. Spondin 1 may interact with this and other integrins to promote viability and 
affect steroidogenesis. A broader approach whereby global gene expression changes were 
measured either by microarray or RNA-seq would also be useful. 
5.6.3 Spondin 1 as a Diagnostic Biomarker  
Now that ovarian roles in viability and angiogenesis have been identified for 
Spondin 1, its status as an ovarian cancer biomarker should be studied more extensively. 
mTORC1 is currently a target for therapy in ovarian cancer due to its increased activity in 
the disease, so Spondin 1, as a possible mTORC1 regulator, could be a target as well. If 
Spondin 1 does indeed play a role in stabilizing blood vessels following angiogenesis, its 
role in disease progression may be two-fold. Studies should be undertaken to evaluate the 
suitability of Spondin 1 as a serum biomarker, as it could possibly be a better diagnostic 
and prognostic indicator than the currently used biomarker, CA125. 
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5.7 Conclusion 
It is now clear that Spondin 1 is functional within the ovary. I have shown not 
only that Spondin 1 affects viability and steroidogenesis of ovarian granulosa cells in 
vitro, but that Spondin 1 is important for complete fertility, as evidenced by the 
subfertility of the Spon1
-/- 
female mouse. Therefore further study of Spondin 1 in the 
ovary, particularly in humans, could provide insight into currently unexplained fertility. 
Spondin 1-mediated increased viability and proliferation, and increased stability of 
vasculature as proposed in this work could contribute to development and progression of 
ovarian cancer. Expression status of progesterone and estrogen receptors is considered a 
prognostic marker for several cancers, including ovarian [39, 40]. Often cancers 
overexpressing these receptors are reliant on continued production of their respective 
hormones. Therefore, Spondin 1-mediated changes in steroidogenesis could affect the 
survival and progression of ovarian cancer. The potential role of Spondin 1 in 
angiogenesis is intriguing considering its localization to capillaries in tissues with 
angiogenic growth (ovary and uterus) and tissues where vessels are maintained (kidney). 
This suggests that Spondin 1 may be involved in vascular maintenance in general, and 
may perform this function in other tissues as well. 
 This thesis presents evidence that Spondin 1 plays an important role in 
maintaining ovarian fertility and expands the current knowledge of Spondin 1 functions. 
Future investigations into the specific mechanisms of Spondin 1-mediated increases in 
viability and proliferation, Spondin 1 regulation of steroidogenesis, and Spondin 1’s role 
in angiogenesis will help to create a more complete picture of Spondin 1’s role in the 
ovary. Hopefully, these studies and future work will have implications for therapeutic 
intervention in infertility and ovarian cancer. 
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Appendix A 
 
 
Appendix A. Steroid hormones and the steroidogenesis pathway. 
The steroidogenesis pathway in the ovary from cholesterol to 17β-estradiol. Steroid 
hormones are written in bold and not enclosed. Steroid enzymes are written beside the 
reactions they catalyze. STAR – steroid acute regulatory protein, transports cholesterol 
from the outer to the inner mitochondrial membrane. CYP11A1 – cholesterol side chain 
cleavage enzyme, cleaves cholesterol to form pregnenolone. HSD3B1 - 3β-
hydroxysteroid dehydrogenase, dehydrogenates pregnenolone, 17α-pregnenolone or 
dehydroeppiandrostenedione to form progesterone, 17α–progesterone or 
androstenedione, respectively. CYP17A1 - 17α-hydroxylase, adds a hydroxyl group to 
pregnenolone or progesterone and splits the side chain off of 17α-hydroxy –pregnenolone 
or –progesterone to form dehydroepiandrostenedione or androstenedione, respectively. 
HSD17Bx - 17β-hydroxysteroid dehydrogenases, convert androstenedione to testosterone 
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and estrone to 17β-estradiol by hydrogenation. CYP19A1 – aromatase, converts 
androstenedione to estrone and testosterone to 17β-estradiol by oxidation and elimination 
of a methyl group. Inset: Chemical structures of progesterone, testosterone, and 17β-
estradiol.  
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Appendix B 
 
 
Appendix B. Apoptosis array comparing BSA-treated and Spondin-1 treated KGNs. 
Apoptosis array comparing protein lysates from BSA-treated (control) KGNs with 
Spondin 1-treated KGNs. Proteins present on the assay include but are not limited to: 
Bad, Bax, Bcl-2, Pro-caspase-3, cleaved caspase-3, Claspin, Hif-1 α, HSPs, Livin, 
Phospho-p53s, and Survivin. The assay was performed twice and no differences between 
treatments were found.  
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Appendix C 
 
Appendix C. Red-green intensity plots of merged images in Chapter 3. 
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Plots of the intensity of red and green fluorescence in merged images of localization of 
SPON1 (green) with PECAM1, DES, or ACTA2 (red). Higher intensity of individual 
colours represents areas where there is little to no overlap between red and green, while 
lower intensity represents overlap. Fig. 3-3, A, B, and C represent SPON1 with PECAM1 
in the ovary and shows high overlap. Fig. 3-4 represents SPON1 with A) DES and B) 
ACTA2 and shows overlap of SPON1 with DES but localization of DES to places where 
SPON1 is not, and not very much overlap between SPON1 and ACTA2. Fig. 3-5 shows 
high overlap between SPON1 and PECAM1 in the uterus. Fig. 3-6 A shows little overlap 
overall between SPON1 and DES in the uterus (a-c), with some overlap taking place in 
the myometrium (d-f). Fig. 3-6 B shows almost no overlap between SPON1 and ACTA2 
in the uterus. 
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Appendix D 
 
Gene Role in Folliculogenesis 
Akr1c18 
Aldo-keto reductase family 1, member C18 or 20α-
hydroxysteroid dehydrogenase, converts progesterone 
to 20α-dihydroprogesterone during breakdown of the 
corpus luteum 
Amh 
Anti-mullerian hormone, suppresses activation of 
primordial follicles and response of secondary follicles 
to FSH 
Cyp11a1 
Cholesterol side chain cleavage enzyme, converts 
cholesterol to pregnenolone 
Cyp19a1 
Aromatase, converts androstenedione to estrone and 
testosterone to 17β-estradiol 
Lhcgr 
Luteinizing hormone/chorionic gonadotropin receptor, 
involved in response to LH 
Pgr 
Progesterone receptor, involved in response to 
progesterone 
Ptgfr 
Prostaglandin F receptor, involved in corpus luteum 
formation and breakdown 
Ptgs2 
Prostaglandin-endoperoxide synthase 2, important for 
cumulus expansion and ovulation 
Scarb1 
Scavenger receptor class B member 1, receptor 
involved in uptake of cholesterol by ovarian cells 
Sox9 
SRY-box 9, development gene involved in female to 
male sex reversal, regulates transcription of Amh 
Star 
Steroid acute regulatory protein, moves cholesterol 
across the mitochondrial membrane 
Appendix D. List of Genes measured for changes in mRNA expression between 
Spon1
-/-
 ovaries and Spon1
+/+ 
ovaries in Chapter 4. 
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Appendix E. 
 
 
Appendix E. Simplified model of proposed Spondin 1 pathways in the ovary. 
Proposed mechanisms by which Spondin 1 might affect cell viability and proliferation, 
steroidogenesis, and angiogenesis. A) Signalling through either APP, LRP8, VLDLR or 
some combination of these receptors, SPON 1 promotes phosphorylation of DAB1. 
DAB1 activates PI3K signalling which phosphorylates AKT. AKT phosphorylation of 
PRAS40 removes PRAS40 from the mTORC1 complex thereby activating mTORC1 
signalling which affects many cellular processes including cell growth and viability. 
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SPON1 may also signal to LRP8 and VLDLR to increase cholesterol transport into the 
cell for steroidogenesis. B) SPON1 binds the latent TGFβ/LTBP/LAP complex and 
removes LTBP and LAP which activates TGFβ. TGFβ can then signal through one of its 
receptors, here represented as TGFβR, and turn on TGFβ signalling, either through PI3K 
to mTORC1 (as shown here) or via another pathway, to promote cell viability and 
proliferation. C) SPON1 may signal through or block signalling of an integrin to effect 
the process of angiogenesis and potentially other cellular processes, such as viability and 
steroidogenesis. SPON1 – Spondin 1; APP – amyloid precursor protein; LRP8 – low-
density lipoprotein receptor related protein 8; VLDLR – very low density lipoprotein 
receptor; DAB1 – disabled 1; PI3K – phosphoinositide 3-kinase; AKT – protein kinase 
B; mTORC1 – mammalian target of rapamycin complex 1; PRAS40 – proline-rich AKT 
substrate of 40 kDa; TGFβ – transforming growth factor β; LTBP- latent TGFβ binding 
protein; LAP – latency-associated peptide; TGFβR – TGFβ receptor.  
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Appendix F 
 
Appendix F.  Co-localization of SPON1 and PECAM1 in the kidney. 
Immunfluorescence by confocal microscopy showing co-localization of SPON1 (red) and 
PECAM1(green) in the kidney. DAPI (blue) shows nuclei of cells. The small round 
structures are glomeruli, spherical networks of capillaries that filter blood.  SPON1 
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localizes to the vasculature, as marked by the location of PECAM1, especially to the 
capillaries within the glomeruli. B is a magnified image of A, and the merged image of B 
is shown larger for clarity.  
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Appendix G 
 
Appendix G. Expression of Vegfa and Pecam1 is not altered following gonadotropin 
treatment in Spon1
+/+
 and Spon1
-/-
 ovaries. 
mRNA expression of Vegfa and Pecam1 in Spon1
+/+
 and Spon1
-/-
 ovaries following eCG 
treatment or eCG treatment followed by hCG treatment for 4, 16, or 24 hours. There was 
significant differences for treatment for both genes as determined by two-way ANOVA, 
Vegfa – F (3, 38) = 6.452, P <0.01, Pecam1 – F (3, 38) = 7.925, P < 0.001. There was no 
significant difference for genotype overall or by individual treatment.   
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